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Proton therapy offers a reduction in dose to normal tissue compared to 
conventional photon-based radiotherapy. This is of particular benefit for 
pediatric patients as the majority are expected to become long-term survi-
vors. Children are therefore often referred to proton therapy in order to 
reduce the risk of radiation induced side effects. Protons are also slightly 
more biologically effective compared to photons, quantified by the clinically 
applied relative biological effectiveness (RBE) of 1.1. However, both exper-
imental and clinical data points to a variable RBE, which depends on tissue 
type, dose level, biological endpoint, and the linear energy transfer (LET). 
Multiple variable RBE models have therefore been developed with the aim 
of quantifying the RBE variation. 
Brain tumor patients are often at high risk of radiation damage to the 
brainstem - a vital organ where injury can lead to devastating side effects. 
Minimizing doses to the brainstem has therefore a high priority during treat-
ment planning. However, the brainstem may also be adversely affected by 
the LET and variable RBE, factors that are not explicitly accounted for in 
routine proton therapy. In this PhD project, for both double scattering and 
intensity modulated proton therapy (IMPT), the LET and variable RBE in 
the brainstem for pediatric brain tumor patients were studied using the 
FLUKA Monte Carlo (MC) code. 
In the first part of this project, the LET and RBE in the brainstem were 
studied for different tumor locations relative to the brainstem. Furthermore, 
techniques for reducing the LET in critical organs by changing the treat-
ment field setup were explored (Paper I). Mean LET values in the brainstem 
more than doubled depending on the tumor location (3.2-6.6 keV/μm), how-
ever, the location with the highest brainstem LET values also had the lowest 
variable RBE-weighted mean dose in the brainstem (1.8-54.0 Gy(RBE)). 
Changing treatment field angles reduced the mean LET in the brainstem 
by 32%, however, with slightly increased brainstem dose. The results 
demonstrate that the LET and variable RBE-weighted dose are strongly 
influenced by tumor location and field configuration, and that both LET 
 
v 
and variable RBE-weighted dose must be carefully considered when altering 
treatment plans. 
In the second part, multiple variable RBE models in treatment for pedi-
atric brain tumors were investigated. The spatial agreement of isodose vol-
umes from the models relative to the RBE of 1.1 were compared, focusing 
on the full brainstem and brainstem substructures (Paper II). Application 
of different model specific parameters were also explored. The RBE-
weighted dose calculated from RBE models was highly dependent on the 
applied parameters, and also differed across models. Furthermore, the spa-
tial agreement between different models decreased rapidly for higher doses, 
illustrating that the RBE effect is most critical at high doses and low vol-
umes, where dose constraints commonly are applied. Hence, using RBE 
models in clinical settings requires model specific dose constraints.  
The majority of follow-up data from proton therapy come from patients 
treated with double scattering (DS) proton therapy. Therefore, a DS nozzle 
was implemented in the FLUKA MC code in order to obtain LET and var-
iable RBE for previously treated patients (Paper III). After calibration, ex-
cellent agreement between measurements and MC simulations was achieved 
with range differences of spread-out Bragg peaks generally below 1 mm and 
lateral penumbra differences less than 1 mm. Recalculation of dose distri-
butions in FLUKA were compared to original patient doses from the treat-
ment planning system, with dose differences below 2%. LET and variable 
RBE were furthermore obtained for these patients. 
In the final part of this project, the DS nozzle implementation was used 
to recalculate 36 pediatric brain tumor patients in a retrospective case-con-
trol study where nine patients had experienced symptomatic brainstem tox-
icity. Differences in LET and variable RBE-weighted dose between cases 
and controls were examined for the full brainstem as well as multiple brain-
stem substructures. Median and maximum LET were on average higher for 
cases vs. controls for all substructures, with the highest difference in median 
LET of 15% in one of the substructures. Average differences between cases 
and controls increased for variable RBE-weighted doses compared to a fixed 
RBE of 1.1. While there was large interpatient variability for both LET and 
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variable RBE-weighted doses, the average higher LET to the brainstem 
could be a contributor to brainstem toxicity. The results warrant individual 
assessment of LET/RBE for patients at risk of brainstem toxicity. 
Overall, this thesis has shown that elevated LET and increased RBE may 
occur in the brainstem for pediatric patients with brain tumors which could 
further contribute to brainstem toxicity. Clinical implementation of LET 
and variable RBE-weighted dose calculation is therefore well justified.  
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  1 Introduction 
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1 Introduction 
In 2020, an estimated 19.3 million individuals were diagnosed with cancer 
(The Global Cancer Observatory, 2020). Nearly 10 million people lost their 
life to the disease, counting for 1 in 6 of all deaths. In developed countries, 
cancer usually ranks as the first or second leading cause of death for people 
below the age of 70 (Sung et al., 2021). While cancer has a lot of risk factors, 
such as tobacco use and radiation exposure, the most prominent factor is 
age, with an average of 67 years at the diagnosis of cancer (Ruddon, 2007). 
Nevertheless, children are also at risk of getting cancer, and it is the leading 
cause of non-accidental death between the ages 1-14. Fortunately, survival 
rates for childhood cancer have increased rapidly the last 50 years, from 
58% in the 1970s to above 80% today (Kassam et al., 2018). With high rates 
of survival, the second priority is to decrease late effects and morbidity 
following cancer treatment. 
The main modalities of cancer treatment include surgery, chemotherapy, 
immunotherapy, and radiotherapy. While all modalities have advantages, 
an estimated 50% of all cancer patients could benefit from radiotherapy 
(Barton et al., 2014). External radiotherapy is a non-invasive treatment 
method, intended to kill or control malignant cells, while at the same time 
sparing healthy tissue. Traced all the way back to 1895 when Wilhelm Rönt-
gen discovered x-rays (Röntgen, 1895), patients have been treated with ra-
diation for almost thirteen decades. During these years, radiotherapy with 
x-rays has steadily evolved from using photons with kilovoltage (kV) ener-
gies delivered by radium tubes to megavoltage (MV) energies using cobalt-
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60 machines. Radiotherapy was further revolutionized by the introduction 
of the linear accelerator in 1948 and later by three-dimensional image ac-
quisition of the patient using computed tomography (CT) and magnetic 
resonance imaging (MRI) (Thariat et al., 2013). Over the years, new tech-
niques for delivering the radiotherapy were also introduced, such intensity 
modulated radiotherapy (IMRT) and volumetric modulated arc therapy 
(VMAT), greatly increasing the dose conformity. All these advancements 
have continuously improved the delivery precision of radiotherapy. 
During the 20th century, radiotherapy using other particles such as protons, 
neutrons, and electrons has also been explored and used for cancer treat-
ment. The advantages of therapeutic proton therapy compared with con-
ventional photon radiotherapy were first suggested and described by Robert 
Wilson (1946). The suggestion was based on the finite proton range, the 
small lateral spread and that the proton ionization per unit length is in-
versely proportional with the energy. This results in a maximum dose dep-
osition in the last centimeter of the proton range giving rise to the so-called 
Bragg peak. Hence, in contrast to photons, protons avoid exit doses and 
greatly reduce the entrance dose, providing an intrinsic increase in dose 
conformity. Patients have been treated with protons since the 1950s, but 
the treatment was in the beginning considered experimental and proton 
therapy was only conducted in research facilities. It was not until the 1990s 
that the first hospital-based facility was built. Since then, the number of 
facilities and treated patients have increased rapidly (PTCOG, 2021a, 
2021b).  
  1 Introduction 
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Protons and photons interact with materials based on different physical 
principles. Protons are more densely ionizing, leading to a slight increase in 
the biological effect compared to photons - termed the relative biological 
effectiveness (RBE). The clinically used RBE for protons have been set to 
1.1 as recommended by the International Commission on Radiation Units 
and Measurements (ICRU, 2007), meaning that protons are characterized 
to be 10% more biological effective compared to photons. While a generic 
RBE has many advantages, such as simplifying the task of transferring clin-
ical experience and tolerance doses from photon radiotherapy to proton 
therapy, it is well known that the RBE is not constant. Experiments have 
shown that the proton RBE is a variable parameter, dependent on quanti-
ties such as the tissue type, physical dose, the linear energy transfer (LET), 
and biological endpoint (Paganetti, 2014).  
Of the around 400 000 adolescents that are diagnosed with cancer each 
year (Steliarova-Foucher et al., 2017), a large portion will receive radiother-
apy. Due to their long life expectancy, pediatric patients are at increased 
risk of experiencing long term morbidity (Oeffinger et al., 2006) and second-
ary cancers (Bhatia & Sklar, 2002). Pediatric patients are therefore often 
prioritized to receive proton therapy due to the increased dose conformity 
of protons. However, as the effect of LET and RBE is currently not quanti-
tatively accounted for in proton therapy clinics, these patients could be 
adversely affected, either in the form of a lack of tumor control or an in-
crease in damage to healthy tissues and organs at risk (OARs). In fact, 
retrospective studies have in recent years indicated a correlation between 
increased RBE and radiation toxicity for patients, including children, 
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treated with proton therapy (Bahn et al., 2020; Bolsi et al., 2020; Eulitz et 
al., 2019b; Peeler et al., 2016; Wang et al., 2020; Ödén et al., 2020). These 
results warrant further investigation. 
Monte Carlo (MC) codes are highly versatile tools that can be useful in 
clinical research regarding radiation treatment. In this PhD project, a gen-
eral-purpose MC code was used to study the effect of the variable RBE and 
LET, focusing on pediatric brain tumor patients treated with proton ther-
apy. This also required the implementation and commissioning of a proton 
therapy treatment nozzle into the MC code.  
 
  2 Radiation physics 
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2 Radiation physics 
2.1 Proton beam interactions 
Radiotherapeutic protons interact with matter by three distinct processes: 
stopping by inelastic collisions with atomic electrons, scattering by elastic 
collisions with atomic nuclei, and non-elastic nuclear interactions. The first 
two processes are the most common and are well described by theoretical 
models. The latter does not follow any simple theory but can be treated 
using correction factors (Gottschalk, 2011). While these interactions occur 
for all heavy charged particles, the focus will be specifically on proton inter-
actions. 
2.1.1 Stopping power 
Protons traversing matter will inelastically collide with the much lighter 
atomic electrons, either exciting or ionizing the electrons. In each interaction, 
a certain amount of proton energy is transferred to the electrons. Due to 
the large mass difference between the particles, protons usually lose only a 
small fraction of the energy per collision. However, these collisions are so 
frequent that the proton energy continuously decreases, slowing down the 
proton. Intrinsically, the longer a proton interacts with an electron the more 
energy it will lose. Thus, slower protons lose more energy, resulting in an 
increasing energy loss for increasing depth, giving rise to the Bragg peak 
where the maximum energy loss occurs (Figure 2.1) (Gottschalk, 2011). The 
Bragg peak is the main advantage of protons over photons in radiotherapy, 
since by adjusting the proton energy, the Bragg peak can be aimed directly 
2.1 Proton beam interactions  
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in the target volume, with only a negligible amount of dose deposited be-
yond this point. 
 The energy loss per unit length is termed the stopping power. The stop-
ping power of a projectile of charge, 𝑧𝑧, and mass, 𝑚𝑚, in a material of atomic 
number, 𝑍𝑍, and atomic mass, 𝐴𝐴, can be described by the Bethe Bloch equa-


















where 𝑁𝑁𝐴𝐴 is Avogadro’s number, 𝑟𝑟𝑒𝑒 is the classical electron radius, 𝑚𝑚𝑒𝑒 is 
the electron mass, 𝑐𝑐 is the light speed in vacuum, 𝛽𝛽 = 𝑣𝑣/𝑐𝑐 where 𝑣𝑣 is the 
speed of the projectile, 𝛾𝛾 is the Lorentz factor (1/�1 − 𝛽𝛽2), 𝑊𝑊𝑚𝑚𝑚𝑚𝑚𝑚 is the 
maximum energy transferrable in a single collision, 𝐼𝐼 is the ionization po-
tential, 𝛿𝛿 is the density correction and 𝐶𝐶 is the shell correction. Focusing 
only on protons in the clinical energy range (3-300 MeV), by disregarding 
the corrections and inserting constants, equation (2.1) can be simplified to 









− 𝛽𝛽2�. (2.2) 
For clinical proton energies, 1/𝛽𝛽2 is the dominant term, illustrating the in-
crease in stopping power for decreasing velocity.  
The energy loss of protons is a stochastic process. In a monoenergetic 
proton beam, protons will interact randomly such that they stop at slightly 
different depths. This phenomenon is called range straggling, an effect that 
ultimately widens the pristine Bragg peak in depth. The straggling for pro-
tons in water can be approximated by 0.012 · range, leading to an increase 
  2 Radiation physics 
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in the absolute width of the proton beam for higher ranges (Gottschalk, 
2011). Another contributor to the Bragg peak width is the energy spread. 
The energy spread of a proton beam increases for instance when the beam 
traverses a medium such as a degrader used for regulating the proton beam 
energy. The energy spread is dependent on the initial beam energy with 
lower energies resulting in higher relative energy spreads (Schippers, 2012).  
Various definitions can be used to characterize the range of a proton beam. 
A common definition is the mean projected range classified as the depth of 
where 50% of the protons stops, not accounting for nuclear interactions 
(Paganetti, 2012). This corresponds to the depth in water where the distal 
80% (d80%) dose of the pristine Bragg peak occurs (Moyers et al., 2007). 
An advantage of using the mean projected range is that it is independent of 
the energy spread (Paganetti, 2012).  
 
Figure 2.1 a) Stopping power of protons in water as a function of kinetic energy. Figure 
created using data from Berger et al. (2017). b) 150 MeV monoenergetic proton beam in 
water. The solid line shows the dose deposit in the form of a pristine Bragg peak. The 
dashed line shows the fluence of the proton beam. Figure created from Monte Carlo sim-
ulations. 
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2.1.2 Multiple Coulomb scattering 
In addition to slowing down through inelastic interactions with electrons, 
protons also undergo electromagnetic elastic collisions with the atomic nu-
clei - a process termed multiple Coulomb scattering (MCS). In almost every 
single collision, the proton is deflected by an almost negligible angle - with 
rare occurrences of collisions with large scattering angles. As the majority 
are small-angle deflections, the sum will result in an approximately Gaussian 
angular distribution. The MCS distributions are well-described by the 
Moliére theory (Molière, 1947, 1948) which is widely used and has been 
shown to have an accuracy of within 1% (Gottschalk, 2011). As the theory 
is quite complex it will not be included here. However, others have devel-
oped simpler scattering theories (but of comparable accuracy) such as 
Highland (1975) who derived his formula by fits to the Moliére theory. The 
characteristic multiple scattering (CMS) angle for protons can then be cal-
culated using (Highland, 1975): 











where 𝑝𝑝 and 𝑣𝑣 is the particle momentum and speed, respectively, 𝐿𝐿 is the 
target thickness while 𝐿𝐿𝑅𝑅 is the so-called radiation length. The radiation 




,  (2.4) 
where 𝑍𝑍 and 𝐴𝐴 is the atomic number and the atomic mass, respectively, of 
the target medium. For a proton with a certain energy, it is evident from 
the two equations that the CMS angle increases for thicker targets and for 
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materials of higher atomic numbers, while decreasing for higher beam ener-
gies. These dependencies are exploited in passive scattering proton therapy 
as explained in section 4.2.1. Figure 2.2 shows the difference in MCS for a 
carbon target (𝑍𝑍 = 6) and a lead target (𝑍𝑍 = 82). 
 
Figure 2.2 Fluence of a 150 MeV proton beam (0.5 cm full-width half maximum) travers-
ing two different targets. Areal densities, 𝜌𝜌 · Δ𝑑𝑑, have been normalized to illustrate the 
𝑍𝑍 dependence of MCS. Left: 2.5 cm carbon target (𝜌𝜌 = 2.26 𝑔𝑔/𝑐𝑐𝑚𝑚3, 𝑍𝑍 = 6). Right: 0.5 
cm lead target (𝜌𝜌 = 11.35 𝑔𝑔/𝑐𝑐𝑚𝑚3, 𝑍𝑍 = 82). Figures created from Monte Carlo simulations. 
2.1.3 Non-elastic nuclear interactions 
Non-elastic nuclear interactions occurs when a proton collides with atomic 
nuclei in a given material and the kinetic energy is not conserved. This is in 
contrast to MCS, which are elastic nuclear interactions. Non-elastic nuclear 
interactions can result in excitation of nuclei or nucleus breakup leading to 
secondaries such as secondary protons, photons, neutrons, heavy particles 
such as alphas and recoiling residual nucleus. If a so-called primary proton 
undergoes a non-elastic interaction, it will no longer be characterized as a 
primary particle but as a secondary particle. This is because it is impossible 
to tell if the proton is the incident particle or if it originates from the atomic 
nuclei (Gottschalk, 2011).  
2.2 Linear energy transfer  
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For a 160 MeV proton beam in water, approximately 20% of the protons 
undergo a nuclear interaction (Gottschalk, 2004). The main effect of these 
interactions is that primary protons are stopped before reaching the Bragg 
peak, resulting in a few consequences: The dose in the peak region decrease 
since primary protons are removed from the peak, the dose before the Bragg 
peak increase as the secondaries have shorter ranges and stop upstream, and 
an immediate increase in dose also occurs a few centimeters within the ma-
terial where the interactions reach equilibrium. Furthermore, secondary par-
ticles usually have large angles relative to the incoming protons, which can 
lead to minor dose deposition far from the beam path, in particular for 
neutral secondaries such as neutrons (Gottschalk, 2011). 
2.2 Linear energy transfer 
The linear energy transfer (LET) is mean energy lost due to electronic 
interactions per unit length by an ionizing particle, such as a proton. It is a 
measure of the ionization density of a particle and is closely related to the 




where 𝑑𝑑𝑑𝑑 is the transferred energy in 𝑘𝑘𝑀𝑀𝑀𝑀  and 𝑑𝑑𝑙𝑙 is the length in 𝜇𝜇𝑚𝑚.  
When a proton interacts with matter, it will ionize and produce secondary 
electrons. Many of these electrons will travel a certain distance (away from 
the incoming particle trajectory) and further ionize the material. Such elec-
trons are termed delta rays. It is therefore often of interest to only look at 
the energy transferred in vicinity of the incoming particle trajectory, hence 
a maximum energy transfer, Δ, can be applied. This is called the restricted 
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LET (LETΔ) where delta rays with kinetic energies above Δ are excluded. 
If no Δ is defined, all delta rays are included and the LET is called the 
unrestricted LET (LET∞, but most often denoted simply as LET). The 
LET∞ is equal to the so-called electronic stopping power, 𝑆𝑆𝑒𝑒𝑒𝑒, which is the 
stopping power when only considering the interactions with the atomic elec-
trons of the material (ICRU, 2011).  
Along each point in a proton track there will be a variance in the energy 
transferred per unit length from the protons, giving rise to a spectrum of 
LET values. However, simplifying the characterization of LET is often 
preferred, usually accomplished by calculating an average LET in each point. 
There are two major approaches of averaging the LET; the dose-averaged 
LET (LETd), most commonly used in proton therapy, and the track-
averaged1 LET (LETt). In LETt, the relative fluence of the ionizing particles 
is used as a weighting factor. For a location, 𝑧𝑧, the LETt of protons can be 













where 𝑆𝑆𝑒𝑒𝑒𝑒 is the electronic stopping power (i.e., the unrestricted LET) for 
the protons and 𝛷𝛷(𝑑𝑑, 𝑧𝑧) is the fluence of the protons with kinetic energy 𝑑𝑑. 
For the alternative, LETd, the LET is weighted by the absorbed dose. It is 
defined as (Guan et al., 2015): 
𝐿𝐿𝑑𝑑𝐿𝐿𝑑𝑑(𝑧𝑧) = 













1 Also referred to as fluence-averaged LET or fluence-weighted LET (LETf). 
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For a proton beam, both the LETt and LETd will be reasonably low (and 
nearly equal) when entering the material. However, as the as protons 
traverse and begins to stop, the LET will increase rapidly, with LETd having 
the steepest curve (Figure 2.3).  
 
Figure 2.3 Dose (solid line) from a 150 MeV proton beam in water (left y-axis). The 
corresponding LETd (dashed line) and LETt (dotted line) from primary and secondary 
protons are also shown for dose > 1% (right y-axis). Figure created from Monte Carlo 
simulations. 
2.3 Proton beam parameters 
In proton beam therapy, a number of different parameters are used to 
define a proton beam. The parameters mentioned below are only valid for 
passively scattered protons where an explicit spread-out Bragg peak (SOBP) 
is defined. In pencil beam scanning, proton treatment fields are 
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characterized through each pristine proton pencil beam individually, by 
specification of the pencil beam energy, weight, direction, spot size etc.  
2.3.1 Spread-out Bragg peak 
To treat a target volume with protons, a single pristine Bragg peak is 
usually too narrow to cover the tumor with dose along the beam direction. 
The solution is to combine several pristine Bragg peaks with decreasing 
energies and weights to produce an SOBP. The concept of the SOBP was 
introduced in Robert Wilsons original paper (Wilson, 1946). He suggested 
that a rotating wheel with steps of variable thickness could be used for the 
purpose of creating an SOBP. This device is today known as a range mod-
ulator (RM) wheel and is widely used in proton therapy (Schippers, 2015).  
An SOBP should in general have a flat dose plateau in order to deliver a 
homogeneous dose to the tumor. This is achieved by properly weighting 
each individual Bragg peak (Figure 2.4a). The peak with the highest energy 
is usually the one assigned the highest weight. The range of the most distal 
peak, i.e., the range of the SOBP, should coincide with the distal end of the 
target volume. While the range of a proton beam can be defined by the 
mean projected range (depth of the d80% dose) as touched upon in section 
2.1.1, in clinical proton therapy, the range of a proton beam is usually de-
fined at the d90% dose due to historic reasons (Paganetti, 2012). The mod-
ulation width of the SOBP determines the length of the dose plateau. The 
modulation width is specified as the distance from d90% dose to either the 
proximal 90% (p90%) dose or the p98% dose, depending on the standard 
chosen by the treatment facility (Figure 2.4a) (Engelsman et al., 2009). 
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As a result of range straggling and energy spread, the distal part of the 
SOBP has a certain slope. This is called the distal dose fall-off and is defined 
as the distance between the positions of the d20% and the d80% dose (Fig-
ure 2.4a) (ICRU, 2007).  
 
Figure 2.4 (a) Spread-out Bragg peak (SOBP) created from multiple pristine Bragg peaks. 
Specifications of SOBP range, distal dose fall-off and modulation widths are also illus-
trated. (b) Lateral profile alongside lateral penumbra definitions. Figures created from 
Monte Carlo simulations. 
2.3.2 Lateral profile and field size 
A tumor will also have a certain extension perpendicular to the beam 
direction. Hence, the beam must also be spread laterally. Techniques for 
doing that are detailed in section 4.2. It is beneficial to have a sharp lateral 
penumbra as this makes it possible to spare healthy tissue adjacent the 
target volume. The lateral penumbra is usually described as the distance 
between the lateral 20% to 80% dose level, but the distance between the 
50%-95% dose levels is also used. Furthermore, the field size is defined as 
the distance between 50% dose levels (Figure 2.4b) (Lu & Flanz, 2011). 
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3 Radiobiology 
When treating a cancer patient with radiation, the general goal is to kill 
malignant cancer cells by inactivating their reproductive ability. This is 
achieved by damaging or destroying the cell DNA. By irradiating cells with 
ionizing particles, a large number of lesions occur in the DNA. Most of these 
are in the form of single-strand break (SSB) where either one of the DNA 
strands are broken or both are broken but with a large separation between 
the breaks. In SSB, the damage is usually quickly repaired, but incomplete 
repair may also occur which can lead to cell mutation or cell death. A more 
ideal form of DNA damage is when the two DNA strands are broken oppo-
site each other or in close proximity. This is termed double-strand break 
(DSB) and is generally more difficult to repair compared to SSB (Hall & 
Giaccia, 2012).  
In proton therapy, DNA damage can occur when the incident protons or 
released delta rays hits the DNA. This is called direct action and is more 
pronounced at higher LET. Another effect is so-called indirect action where 
protons or delta rays ionize water releasing free radicals which damage the 
DNA via chemical reactions. This is the most dominant effect at low LET 
and in conventional photon therapy (Paganetti, 2011b). 
The main reason that high LET particles are more biological effective is 
the spatial distribution of DNA lesions within the cells. Particles with high 
LET i.e., high ionization density, generates more clustered damage within 
the DNA compared to low LET particles. Clustered DNA damage is com-
plex and is more difficult to repair compared to the more spatially 
3.1 The linear quadratic model  
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distributed ionization tracks within a cell from low LET particles (Paganetti, 
2011b).  
3.1 The linear quadratic model 
The linear quadratic (LQ) model is a very simple mathematical model 
that has been widely adapted in radiotherapy to describe cell survival 
(Joiner, 2009). In the model, the fraction of surviving cells 𝑆𝑆 as a function 
of delivered dose 𝐷𝐷, can be described by: 
𝑆𝑆(𝐷𝐷) = 𝑀𝑀−𝛼𝛼𝛼𝛼−𝛽𝛽𝛼𝛼2 , (3.1) 
where 𝛼𝛼 and 𝛽𝛽 are tissue specific LQ model parameters. A common inter-
pretation of the model is that the linear component 𝑀𝑀−𝛼𝛼𝛼𝛼 represents damage 
from so-called single-track events where a single hit is required to inactivate 
the cell. The quadratic term 𝑀𝑀−𝛽𝛽𝛼𝛼2 arise from two-track events where two 
consecutive hits are required to achieve cell-kill (McMahon, 2018). The α/β 
ratio determines the curvature of the survival curve and reflects the frac-
tionation sensitivity of the cell type or tissue. The unit of the 𝛼𝛼/𝛽𝛽 ratio is 
Gy, and it is equal to the dose level where the linear and quadratic contri-
butions of the survival curve are equal (Figure 3.1). 
Tumor tissue and other radiosensitive and early responding tissues such 
as the skin and bone marrow are generally associated with high 𝛼𝛼/𝛽𝛽 ratios. 
There are, however, many exceptions where for instance prostate tumors 
(Bentzen & Ritter, 2005) and liposarcomas (Thames & Suit, 1986) have 
been linked with low 𝛼𝛼/𝛽𝛽 ratios. Nevertheless, low ratios are mostly char-
acteristic for late responding tissues such as the central nervous system 
(Bentzen & Joiner, 2009; McMahon, 2018). While these are general trends 
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for early and late reacting tissue, it must be emphasized that 𝛼𝛼/𝛽𝛽 ratios are 
often associated with large uncertainties (van Leeuwen et al., 2018). 
 
Figure 3.1 Survival fraction curves of V79 cells for x-rays (dashed line) and 11 keV/μm 
protons (solid line). The red dotted line shows the linear component for the x-rays while 
the green dotted line shows the quadratic component, resulting in an 𝛼𝛼/𝛽𝛽 for x-rays of 
2.8 Gy. The black dotted lines represent the RBE at 10% survival, 𝑅𝑅𝑅𝑅𝑑𝑑10% =
5.8 𝐺𝐺𝐺𝐺
4.4 𝐺𝐺𝐺𝐺 ≈
1.3. Figure created using data from Belli et al. (1998). 
3.2 Relative biological effectiveness 
The relative biological effectiveness (RBE) of protons is defined as the 
dose from some reference radiation 𝐷𝐷𝑚𝑚 divided by the proton dose 𝐷𝐷𝑝𝑝 to 





In proton therapy, the reference radiation is generally photon radiation. 
Finding isoeffective dose levels for protons and photons for various 
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endpoints is of great benefit in proton therapy as the vast amount of clinical 
data for conventional photon therapy can then be exploited and translated 
to proton treatment. To have a consistent and simple translation, the RBE 
for protons relative to photons has been set to 1.1 (RBE1.1). Hence, protons 
are considered to be 10% more biologically effective than photons in proton 
therapy treatments. By multiplying the RBE with the physical proton dose, 
the so-called biological dose is obtained, also termed the RBE-weighted dose, 
with unit Gy(RBE) (Paganetti et al., 2019). 
The RBE1.1 is mainly based on animal experiments conducted in the 1960-
70s (G. V. Dalrymple et al., 1966; Glenn V. Dalrymple et al., 1966; 
Paganetti, 2018; Tepper et al., 1977; Urano et al., 1980). While variations 
in the RBE were seen, the RBE1.1 was deduced as an average value over 
multiple endpoints, at the center of the target volume and doses of 2 
Gy/fraction. It was furthermore decided to use a conservative RBE to en-
sure tumor control during proton therapy. The RBE1.1 has since been 
adapted by proton therapy clinics around the world.  
There has been published a great amount of experimental data of the 
proton RBE for clonogenic cell survival. Multiple studies analyzing such 
data have shown a proton RBE dependency on LET, dose level, tissue type, 
and biological endpoint (Khachonkham et al., 2020; Maeda et al., 2016; 
Mara et al., 2020; Paganetti, 2014). The analysis by Paganetti (2014) 
showed that the RBE for a typical SOBP was found to range from 1.1 in 
the entrance region, to 1.15 in the center, to 1.35 at the distal edge and 
further up to 1.7 at the distal dose fall-off. A variable RBE could be of 
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concern if proton treatments based on RBE1.1 would lead to either under-
dosage of the tumor volume or overdosage of healthy tissue. 
3.2.1 LET dependency 
Radiation effects on a cellular level are highly dependent on the track 
structure and dosimetric effects on both micro and nano scales. While the 
LET is a macroscopic quantity that describe the energy loss per unit path 
length, it is considered a reasonable approximation of the complexity and 
concentration of the inflicted damage (Paganetti, 2014). As touched upon 
at the beginning of section 3, for low LET radiation to reach a certain dose 
level, a large amount of ionization tracks is required, effectively leading to 
a homogenous distribution of particle tracks and dose deposit. In contrast, 
due to the increased ionization density from particles of higher LET such as 
protons, clustered and more severe damage is inflicted on the DNA which 
is more difficult to repair, effectively leading to an increased RBE (Paganetti, 
2011b). The RBE-LET dependency for protons has been demonstrated from 
cellular experiments (Figure 3.2).  
Considering that the LET increases with decreasing proton energy (Figure 
2.3), the RBE will also increase, particular in the distal part of the proton 
beam. This effectively leads to an extension of the biological effective proton 
beam range of a few millimeters (Paganetti & Goitein, 2000). It is further-
more recognized that the average LET is higher for proton beams of lower 
ranges as well as smaller modulation widths. The range dependence, alt-
hough relatively small, can be attributed to the lower energy protons that 
are required for shorter beam ranges, leading to an increase in the LET. In 
regards to the modulation width dependency, the LET increases over a 
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smaller area compared proton beam of longer modulation widths, effectively 
increasing the RBE at the center of the SOBP (Paganetti, 2014).  
 
Figure 3.2 Proton RBE at 10% cell survival for V79 cells. The dashed line shows a linear 
fit. Figure created using data from Sørensen et al. (2011). 
3.2.2 Tissue dependency 
Each cell line or tissue type can be associated with a specific 𝛼𝛼𝑚𝑚 and 𝛽𝛽𝑚𝑚 
value from the LQ-model for photon radiation. While there is an expected 
RBE dependency on tissue type (i.e., on (𝛼𝛼/𝛽𝛽)𝑚𝑚), the exact relation is some-
what unclear (Paganetti et al., 2019). There has been published data sug-
gesting that the RBE increases with decreasing (𝛼𝛼/𝛽𝛽)𝑚𝑚 only for (𝛼𝛼/𝛽𝛽)𝑚𝑚< 5 
Gy (Gerweck & Kozin, 1999). The in vitro data studied by Paganetti (2014) 
points to an increase in RBE for decreasing (𝛼𝛼/𝛽𝛽)𝑚𝑚 for protons with LETd 
< 15 keV/μm at 2 Gy/fraction. Nevertheless, there are discrepancies in the 
data, and only a particularly strong dependency is seen for LETd < 
3 keV/μm and even tendencies of decreasing RBE for decreasing (𝛼𝛼/𝛽𝛽)𝑚𝑚 are 
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seen for higher LETd values (Paganetti, 2014). It must, however, be em-
phasized that the data sets studied are largely uncertain. 
3.2.3 Dose dependency 
By decreasing the dose per fraction there is a tendency of increasing pro-
ton RBE for cell survival (Paganetti, 2014). This effect is also illustrated by 
the more pronounced shoulder in the LQ models survival curve for photons 
compared to protons (Figure 3.1) and is particularly pronounced at high 
LET or low (𝛼𝛼/𝛽𝛽)𝑚𝑚. Nevertheless, evaluating in vitro data in regard to dose 
dependency is somewhat difficult. Most of the published experimental data 
have few data points for doses below 2 Gy. Furthermore, assessing cellular 
survival fractions below 0.1%, which generally occur at high doses, is chal-
lenging. The validity of the LQ model below doses of 1 Gy is also question-
able (Paganetti et al., 2019).  
While the exact relationship of the RBE-dose dependency is not known, 
the general trend of increasing RBE for lower doses is a concern for critical 
organs around the distal dose fall-off of the proton beam - an effect that 
comes in addition to the increased LET in the same region.  
3.2.4 Endpoint dependency 
The majority of data on the RBE stems from clonogenic cell survival. The 
RBE is commonly reported using the 10% survival fraction as a biological 
endpoint (Figure 3.1 and 3.2). However, the RBE will depend on the differ-
ent survival fractions.  
Furthermore, while cell survival may be a good surrogate for predicting 
the RBE for tumor control, there are other endpoints that may be more 
relevant, in particular for normal tissue damage (Paganetti et al., 2019). 
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In vivo data are more closely related to clinical outcome compared to in 
vitro data and could provide better estimates for the RBE in regard to 
normal tissue damage. However, in vivo experiments are more costly and 
more prone to uncertainties (Paganetti et al., 2019). There do exist in vivo 
experiments (Sørensen et al., 2017; Saager et al., 2018) indicating the same 
trends for the RBE-LET and RBE-dose dependencies as shown from in vitro 
data, but the RBE is still expected to vary in vivo due to differences in 
biological mechanisms such as immune response and repair mechanisms (Pa-
ganetti et al., 2019). 
3.2.5 RBE models 
Multiple theoretical RBE models have been developed that aim to quan-
tify the RBE variation in proton therapy. These can be divided into three 
main categories: plan-based models, mechanistic models, and phenomeno-
logical models. 
Plan-based models are the simplest type. These are not directly based on 
cell experiments, but rather on data available in the treatment plan such as 
dose and LET, hence the name plan-based. These models typically assume 
a certain normalization factor to obtain an RBE of 1.1 in for instance the 
target volume or in a typical SOBP. While they do not provide RBE values 
directly based on experimental data, they can give insights into the dosi-
metric RBE effects of an increased LET, and also illustrate the potential 
inhomogeneity of the RBE-weighted dose distribution (Paganetti et al., 
2019). They are furthermore useful for LET-based treatment plan optimi-
zation (Unkelbach et al., 2016).  
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Mechanistic models seek to explain biological effects by modelling under-
lying biological processes that lead to lesions or damages on a microscopic 
scale such as DSBs. These events are further quantified and related to over-
all cell survival. Different models have been developed such as the local 
effect model (LEM) (Elsasser et al., 2010; Scholz et al., 1997) and the mi-
crodosimetric kinetic model (MKM) (Hawkins, 1998) clinically used in car-
bon ion therapy in Europe and Japan, respectively.  
 Phenomenological models are based on empirical data from in vitro ex-
periments and make use of the LQ model to quantify cell survival. Not 
taking microscopic processes into account, the models rely on 𝛼𝛼 and 𝛽𝛽 of 
the reference radiation as well as the LETd and dose levels from experiments. 
A multitude of models exist in literature (Carabe et al., 2012; McNamara et 
al., 2015; Rørvik et al., 2017; Wedenberg et al., 2013; Wilkens & Oelfke, 
2004a). For an in-depth review of the available models, the reader is referred 
to Rørvik et al. (2018). The phenomenological models can all be parameter-
ized from the LQ model. Since the proton RBE is defined when the survival 
fraction for proton radiation 𝑆𝑆𝑝𝑝 equals the survival fraction of the photon 
radiation 𝑆𝑆𝑚𝑚, the following relation using equation (3.1) is true:  
𝑆𝑆𝑝𝑝�𝐷𝐷𝑝𝑝� = 𝑆𝑆𝑚𝑚(𝐷𝐷𝑚𝑚) ⇒ 𝑀𝑀−𝛼𝛼𝛼𝛼𝑝𝑝−𝛽𝛽𝛼𝛼𝑝𝑝
2 = 𝑀𝑀−𝛼𝛼𝑥𝑥𝛼𝛼𝑥𝑥−𝛽𝛽𝑥𝑥𝛼𝛼𝑥𝑥2 , (3.3) 
where 𝐷𝐷𝑝𝑝 is the physical proton dose, 𝐷𝐷𝑚𝑚 is the photon dose, 𝛼𝛼𝑚𝑚 and 𝛽𝛽𝑚𝑚 are 
the LQ model parameters for the photons while 𝛼𝛼 and 𝛽𝛽 are parameters for 
the proton radiation. Combining equations (3.2) and (3.3) the proton RBE 
can be expressed by: 
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In general, the RBE will reach its maximum when the dose approaches zero, 
and its minimum when the dose goes towards infinity. Thus, the RBE can 
be derived at the dose extremes: 
lim
𝛼𝛼𝑝𝑝→ 0





































Equation (3.7) is common for all the LQ based phenomenological models. 
They do, however, vary in aspects such as the selection of data points and 
regression techniques from the cell experiments (Rørvik et al., 2018). A dis-
tinction can also be made between models that characterize a linear rela-
tionship between the LETd and RBE, and those that assume a non-linear 
relationship (Rørvik et al., 2017). In contrast to linear RBE models that can 
use the LETd to calculate the RBE, non-linear RBE models require the full 
LET spectra to quantify the RBE.  
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3.3 Variable RBE in a clinical setting 
While it is well established from both in vitro and in vivo experiments 
that the RBE varies depending on the factors outlined in the previous sec-
tion, it is still a question of how the RBE variability affects clinical treat-
ment of patients, with a particular concern for organs and tissues with low 
(𝛼𝛼/𝛽𝛽)𝑚𝑚 and in areas of increased LET. While treatment facilities are aware 
of the potential dangers of elevated LET and RBE, a quantitative evalua-
tion is not common, especially considering that not all facilities have access 
to systems that can calculate LET and RBE. Nevertheless, it is common to 
try to mitigate the impact of a variable RBE, in particular at the end of the 
proton range, by taking certain measures. These include careful selection of 
treatment field angles such that beams do not stop within or near critical 
organs. Another method is to use an increased number of treatment fields 
to lower the field weights and thus the RBE uncertainties (Indelicato et al., 
2014; Paganetti et al., 2019). 
In recent years, a several studies have investigated the correlation between 
a variable RBE and various clinical endpoints such as radiation necrosis and 
disease recurrence (Bahn et al., 2020; Bolsi et al., 2020; Eulitz et al., 2019b; 
Giantsoudi et al., 2016; Niemierko et al., 2021; Peeler et al., 2016; Sethi et 
al., 2014; Underwood et al., 2018; Wang et al., 2020; Ödén et al., 2020). 
There is a lot of variation in the studies such as patient cohort sizes, choice 
of endpoints, diagnoses, and conclusions. Nevertheless, the majority of the 
studies has been able to find a significant correlation between a variable 
RBE and the investigated endpoint. 
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4 Treatment planning and delivery techniques 
4.1 Treatment planning 
In radiotherapy, regardless of the delivery technique, the goal is to dis-
tribute a homogeneous dose to the target volume. At the same time, it is 
important to minimize the dose to surrounding healthy tissue. This requires 
careful treatment planning. 
One of the first steps in treatment planning is usually to acquire anatom-
ical 3D images of the patient with focus on the treatment area. A prerequi-
site for radiotherapy treatment is a CT scan to obtain density information 
of the patient body to allow for calculation of dose distributions. These 
images are often combined with either MRI images or PET (positron emis-
sion tomography) scans to increase soft tissue contrast and to better assess 
the tumor extent and OARs. 
Images from a CT scanner consists of a 3D matrix where each matrix 
element (i.e., voxel) contains a Hounsfield unit (HU). HUs relate to the 
attenuation of x-rays during imaging and are affected by the relative elec-
tron density in the material. The relationship between the HUs and electron 
density is not linear and a calibration curve between the two is required for 
each separate CT scanner (Langen et al., 2015). To create this calibration 
curve, a common approach is the stochiometric method where measure-
ments of x-ray attenuation in tissue equivalent materials are used (Schnei-
der et al., 1996). In proton therapy, most treatment planning systems are 
water-based (tissues are modelled as water of different density) and proton 
beam measurements in treatment facilities are mainly conducted in water. 
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It is therefore of interest to calibrate the HUs in terms of relative stopping 
power ratios to water. These ratios can be derived from a combination of 
the relative electron densities and the Bethe Bloch equation (2.1). The cal-
ibration curves are subject to uncertainties, which can be reduced by for 
instance using dual-energy CT scans or ideally by using proton CT to obtain 
relative stopping power ratios directly from protons (Langen et al., 2015). 
The acquired images from CT, MRI and/or PET form the basis for the 
delineation of the target volume and organs. ICRU has defined important 
volumes used in treatment planning such as the gross tumor volume (GTV), 
clinical target volume (CTV), and planning target volume (PTV). Further-
more, OARs and planning organs at risk volumes (PRV) are usually delin-
eated before patient treatment. The GTV encompass all visible diseased 
tissue while the CTV comprise of the GTV, but also includes areas with 
suspected microscopic cancer tissue. The PTV and PRVs adds additional 
margins to the CTV and OARs, respectively. These margins are defined to 
account for uncertainties such as patient positioning and internal variation 
including organ and target movement. In contrast to the GTV and CTV, 
the margins for the PRVs and PTV are dependent on whether the patient 
is treated with photons or protons as the latter requires additional margins 
due to range uncertainties (Li et al., 2015). However, fixed margins have 
limitations where for instance the PTV margin, while ensuring CTV cover-
age, might compromise OARs. A technique that is becoming more common 
is robust optimization where organ motion and uncertainties are incorpo-
rated into the treatment plan optimization directly based on the CTV, 
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making the concept of a PTV obsolete (Chen et al., 2012; Liu et al., 2012; 
Unkelbach et al., 2018).  
Prior to administering dose to the patient, a treatment plan is created 
using a treatment planning system (TPS). TPSs usually rely on so-called 
inverse planning where a dose planner assigns dose objectives and dose lim-
its to targets and critical organs, in addition to defining treatment field 
angles. Based on the applied criteria, the TPS subsequently optimize the 
treatment plan to provide the best possible dose distribution. A requirement 
in treatment planning is that the optimization process should be relatively 
quick. TPSs therefore generally use so-called pencil beam algorithms to cal-
culate the dose distributions (Hong et al., 1996). Such analytical algorithms 
typically offer an acceptable compromise between calculation time and ac-
curacy. 
Most of the relevant information from the treatment plan is stored in a 
common format called DICOM (Digital Imaging and Communications in 
Medicine). The DICOM CT Image files store the 3D images acquired from 
the CT scan. DICOM RT Struct contains information regarding the delin-
eation of targets, OARs, and other regions of interest. The plan created in 
the TPS is stored in the DICOM RT Plan file containing information such 
as treatment angles, beam energies, isocenter positions, and depending on 
the delivery technique, data regarding the aperture and compensator, or 
spot size data. Lastly, the delivered dose distribution is stored in the DI-
COM RT Dose file. The dose is scored on a grid defined in the TPS, and 
dose values in each scoring voxel are located in the RT Dose file (NEMA, 
2021). Using a common format such as DICOM, simplifies the translation 
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of patient and treatment information between different systems and soft-
ware. 
4.2 Delivery techniques 
To obtain protons with energies suitable for clinical treatment, powerful 
accelerators are required. In proton therapy, particle acceleration is gener-
ally achieved by either a cyclotron or a synchrotron. There are many differ-
ences between the two accelerator types. Cyclotrons usually have a smaller 
footprint and can provide a continuous beam. However, the maximum beam 
energy is generally limited at around 250 MeV and to adjust the beam en-
ergy of the extracted protons, a physical object in the form of an energy 
degrader must be placed in the beam path, resulting in a lower energy beam 
but at the cost of an increased energy spread. Synchrotrons are normally 
larger compared to cyclotrons. As a result, they can produce proton beams 
with much higher energies, as well as accelerate heavier particles such as 
carbon ions to energies suitable for treatment. The beam energy can be 
adjusted within the accelerator, producing sharp monoenergetic particle 
beams. On the other hand, synchrotrons are not able to produce continuous 
beams, but rather beam pulses, ultimately making the energy switching 
more time consuming (Schippers, 2015).  
Proton beam accelerators produce so-called pencil beams with a Gaussian 
profile of a few millimeters (Slopsema, 2011). Since target volumes generally 
have a certain extension, the pencil beam must be spread laterally as well 
as distally after being extracted from the accelerator. This is accomplished 
in the treatment nozzle, which in many treatment facilities is placed in a 
rotating gantry in order to irradiate the patient from different angles 
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(Schippers, 2015). To deliver the proton beam for patient treatment, two 
beam delivery techniques have been dominating: passive scattering (PS) and 
pencil beam scanning (PBS). 
4.2.1 Passive scattering 
Historically, PS has been the most commonly used delivery technique and 
is still used by many proton therapy facilities (PTCOG, 2021a). By employ-
ing different materials and geometrical components in the beam path, the 
narrow pencil beam is spread laterally as well as shaped according to the 
target volumes (Figure 4.1a). While different proton therapy vendors have 
different types of scattering components as well as setups within the nozzle, 
the lateral spreading of the proton beam is based on the same principle: 
multiple Coulomb scattering. A passive treatment nozzle usually employs 
scattering materials of high-Z, such as lead, to achieve a high scattering 
power relative to the energy loss. PS delivery can be divided into so-called 
single scattering or double scattering (DS). Single scattering employs less 
scattering material in the beam path to obtain a relatively narrow and flat 
proton beam - typically used for treatment of small target volumes such as 
ocular melanomas. Field sizes in single scattering generally does not exceed 
a diameter of 7 cm (Slopsema, 2011). In DS, a second additional scatterer 
is used to further spread the beam to achieve treatment fields with sizes up 
to about 25 cm in diameter (Lu & Flanz, 2011). A common type of second 
scatterers are the so-called contoured scatterers. In these, more scattering 
material is located in the center compared to the outer edge. This results in 
a larger fraction of the central protons being scattered to the edges, creating 
a flat profile. However, since the protons reaching the periphery parts of the 
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scatterer traverse less material, the high-Z contoured scatterer is combined 
with a low-Z material such as PMMA to have a uniform energy loss across 
the entire scatterer (Figure 4.1a) (Slopsema, 2011).  
A monoenergetic proton beam, i.e., the pristine Bragg peak, is only a few 
millimeters in depth. As mentioned in section 2.3.1, in order to cover the 
clinical target volume distally with dose, the depth-dose curve must be wid-
ened. This can be done by combining multiple pristine Bragg peaks of de-
creasing range (energy) and weights, resulting in an SOBP with uniform 
dose (Figure 2.4a). Depending on the target extent, the size of the uniform 
dose region can be altered by either adding or reducing the number of pris-
tine Bragg peaks, increasing or decreasing the modulation width, respec-
tively. There are several different techniques to produce an SOBP. The most 
common method is to use an RM wheel. The wheel has steps of varying 
thickness corresponding to the range pull-back of each pristine Bragg peak 
(Figure 4.1a). The angular sizes of the steps vary and determines the weight 
of each Bragg peak. Generally, the thinnest step has the largest size (and 
weight) with decreasing size and thickness for each consecutive step. The 
RM wheel rotates during beam irradiation, resulting in protons traversing 
the different steps of varying thickness and size leading to an SOBP (Slops-
ema, 2011). A treatment nozzle usually has several different wheels that can 
be interchanged in accordance with the requested range and modulation 
width of the SOBP. However, to create SOBPs with flat dose plateaus for 
a range of energies using a limited number of RM wheels, a beam current 
modulation (BCM) is applied to fine tune the weights of the pristine Bragg 
peaks (Lu & Kooy, 2006). Another method to create SOBPs is to use a ridge 
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filter. This filter consists of multiple ridges and valleys, where the ridge 
thicknesses define the pullback of the protons, and the ridge widths deter-
mines the weights. Each requested modulation width requires a separate 
ridge filter, and a library of different filters are usually defined (Mazal et al., 
2015). 
After the scatterers have spread the beam to a uniform lateral distribution 
and the RM wheel, or ridge filter, has created an SOBP, the dose must be 
conformed according to the target area. This is most commonly achieved by 
using an aperture. The aperture is typically milled from a solid block of 
brass. The aperture opening is defined according to the target volume with 
added margins for e.g., setup uncertainties. The aperture material is chosen 
to provide a high stopping power at a relatively low thickness, designed to 
stop all particles outside of the opening (Figure 4.1a) (Slopsema, 2011).  
A range compensator is used to shape the proton dose to the distal edge 
of the target volume. It is desirable to have low scattering power and a high 
stopping power for the compensator. Therefore, it is commonly created from 
a block of low-𝑍𝑍 and (relatively) high density material such as PMMA. The 
compensator is milled such that protons that are to reach the most distal 
parts of the target traverse less material compared to protons that stop at 
shallower depths (Figure 4.1a) (Mazal et al., 2015). 
4.2.2 Pencil beam scanning 
In PBS, two dipole magnets located in the nozzle are used to steer the 
beam in order to “paint” the target volume with dose (Figure 4.1b). This is 
done without the requirement of scattering materials in the beam path as 
well as collimating components (Flanz, 2011).  
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During the optimization process in the TPS, the target volume is assigned 
a certain number of spots covering the entire volume both laterally and 
distally. Each spot will be allocated a certain weight, size, and position in 
𝑑𝑑, 𝑦𝑦 and 𝑧𝑧. The 𝑑𝑑 and 𝑦𝑦 (lateral) positions are adjusted by the dipole mag-
nets while the 𝑧𝑧 position is determined by the beam energy. The weights of 
the spot positions are distributed such that the target receives a homogene-
ous dose. This is either done on a field-by-field basis called single-field opti-
mization, or the weights are assigned in such a way that the dose becomes 
homogeneous only when taking all the treatment fields into account, referred 
to as multi-field optimization or intensity-modulated proton therapy 
(IMPT).  
There are different techniques that can be used to irradiate the spot po-
sitions with the pencil beam. Spot scanning is a technique where each spot 
is irradiated separately, i.e., the beam is turned off between each spot. An-
other technique is to irradiate each spot in each energy layer continuously 
such that the beam is only turned off between energy layers. This technique, 
referred to as raster scanning, is more efficient compared to spot scanning 
(Zhu et al., 2015). It is, however, important that the optimization algorithm 
from the TPS considers the transit dose when moving between spots (Ina-
niwa et al., 2007). 
The spots in the target volume are irradiated one energy layer at the time. 
As there are strict requirements on the spot sizes in PBS, adjusting the 
beam energy within the nozzle by an RM wheel or ridge filter is not done 
(Slopsema, 2011). The energy must be adjusted either directly in the case 
of a synchrotron, or by a degrader at the exit of a cyclotron. The main 
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disadvantage of these methods is the time it takes to change the energy 
which is in the order of a couple of seconds (Zhu et al., 2015). 
PBS systems are the standard for most new treatment facilities and many 
current facilities are making a transition from PS to PBS (Mohan et al., 
2017a). PBS has many advantages compared to passive scattering such as 
larger field sizes, less secondary particles such as neutrons, more conformal 
dose distributions and no patient specific components must be created (Fig-
ure 4.1) (Lu & Flanz, 2011; Mohan & Grosshans, 2017; Shin et al., 2009). 
However, passive scattering is still more robust to patient and organ motion, 
and it is quicker to deliver the dose after the patient has been positioned on 
the treatment table.  
 
Figure 4.1 In passive scattering (a), a pencil beam is spread laterally and distally using 
various components. The dose is conformed according to the target volume by apertures 
and range compensators. In pencil beam scanning (b), the beam steered using dipole 
magnets. Each spot is irradiated by the pencil beam, and the target volume is distally 
divided into energy layers. Red spots in the figure represent irradiated spots, while green 
spots are remaining in the current energy layer. 
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4.3 Monte Carlo simulations 
Analytical pencil beam algorithms used in treatment planning are fast 
and normally sufficiently accurate for patient dose calculations in proton 
therapy clinics (Y Jia et al., 2012; Petti, 1996). Nevertheless, they can en-
counter limitations, especially in low dose regions, in areas of high hetero-
geneity or in the case of metallic implants (Bueno et al., 2013; Catli & Tanir, 
2013; Paganetti et al., 2008; Schuemann et al., 2015; Shin et al., 2017; Yepes 
et al., 2018). Furthermore, most analytical algorithms that are implemented 
in proton therapy clinics does not support LET calculation, which is a pre-
requisite for obtaining variable RBE (Mohan et al., 2017a).  
In contrast to analytical dose calculation algorithms, Monte Carlo (MC) 
simulations use pseudo random sampling from probability density functions 
(PDFs) to calculate how particles interact through different materials. In-
stead of estimating dose distributions by modelling pencil beams as an entity, 
MC codes track each primary particle, including secondary produced parti-
cles, separately. The tracking is performed on a step-by-step basis where for 
each step (typically a small distance) the most probable interaction for the 
tracked particle is sampled from the PDFs (Paganetti, 2011a). 
MC simulations are considered to be the most accurate method of dose 
calculation. However, the precision, i.e., the statistical uncertainty in MC, 
is primarily dependent on the number of primary particles simulated. Hence, 
a large number of particles must be simulated to achieve a given accuracy, 
which can be very time consuming. This is the main reason why general-
purpose MC codes are seldomly used for treatment planning and in daily 
clinical routine. Nevertheless, general-purpose MC codes are highly versatile 
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tools for post-treatment simulations and research purposes. They are nor-
mally highly customizable and can be used to investigate a number of as-
pects during treatment such as very low doses, neutron doses, LET and 
RBE. To build an in-house MC recalculation system, a precise model of the 
treatment head is generally required. This includes careful calibration of the 
MC system to either measurements or the TPS (Paganetti, 2011a). Further-
more, facilitating data flow between the TPS and MC considering differ-
ences in for instance scoring quantities and coordinate systems is important 
(Bauer et al., 2014; Verburg et al., 2016). 
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5 Pediatric brain tumor patients 
From 2015 to 2019, an average annual number of 240 patients between 
the ages of 0 to 19 years old were diagnosed with cancer in Norway. 24% of 
these diagnoses were cancer in the central nervous system, including brain 
tumors (Cancer Registry of Norway, 2020). When treating brain tumors 
with radiotherapy, the brainstem is often at risk of receiving unwanted dose. 
Thus, keeping the brainstem dose below established dose constraints has a 
high priority.  
5.1 The brainstem in proton therapy 
The brainstem is a highly important organ that controls many vital bodily 
functions. It is located in the posterior fossa (Figure 5.1) and is the connect-
ing structure between the cerebrum and the spinal cord. The brainstem 
consists of three main substructures: the midbrain, pons, and medulla ob-
longata. The midbrain controls sensory functions such as visuals and audi-
tory senses, while the pons and medulla oblongata control vital parts in-
cluding cardiovascular and respiratory systems (OpenStax College, 2013). 
In addition to the main brainstem substructures, there are also several fiber 
tracts running from the motor cortex and through the brainstem to the 
spinal cord. These have all important functional roles such as limb move-
ment and sensory discrimination (Hua et al., 2012).  
Due to the brainstem being a very compact organ both structurally and 
functionally, it is very delicate. Small lesions or other kinds of damage to 
the brainstem can be devastating and fatal (Standring, 2016).  
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Figure 5.1 Illustration of the brainstem consisting of the midbrain, pons, and medulla 
oblongata. Figure modified from OpenStax College (2013). 
The incidence of symptomatic brainstem toxicity following proton therapy 
of posterior fossa tumors have been reported between 0% and 16% (Ares et 
al., 2016; Gentile et al., 2018; Giantsoudi et al., 2016; Gunther et al., 2015; 
Indelicato et al., 2014; Macdonald et al., 2013; McGovern et al., 2014). Cur-
rent brainstem tolerance doses are well-established and associated with rel-
ative low occurrences of brainstem toxicity of 2.4% among the three largest 
proton therapy facilities treating pediatric patients in the United States 
(Haas-Kogan et al., 2018). Nevertheless, since the consequences of brainstem 
toxicity are so severe, reducing the incidence even further is of great im-
portance.  
Proton therapy centers may use slightly different brainstem dose con-
straints based on institutional clinical experience (Haas-Kogan et al., 2018). 
There is, however, an ongoing phase III clinical trial (ACNS0831) from the 
Children's Oncology Group (2010), recommending that the goal for the me-
dian dose to the brainstem should be ≤ 52.4 Gy(RBE) and must not surpass 
54 Gy(RBE), based on data from both photon and proton therapy. 
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Although certain studies have published specific dose limits to the center of 
the brainstem (Debus et al., 1997; Indelicato et al., 2014), no official recom-
mendations have been made. Nevertheless, considering that the brainstem 
is a very heterogeneous organ, it has been suggested that specific regions 
might be more radiosensitive (Hua et al., 2012; Meeks et al., 2000; Uh et al., 
2013).  
5.1.1 Specific RBE concerns for the brainstem 
As previously mentioned, the LET increases at the distal edge of proton 
beams, further leading to an increase of the RBE. Brain tumors, and in 
particular posterior fossa tumors, are often located in vicinity of the brain-
stem and the variable RBE is therefore of particular concern for such pa-
tients. Children with brain tumors are also typically treated with doses be-
low 2 Gy(RBE) per fraction (Bates et al., 2020), a dose level where an 
increase in the RBE is expected. Furthermore, the brainstem is considered 
a late-reacting organ and is thus characterized by a low (𝛼𝛼/𝛽𝛽)𝑚𝑚. While the 
specific brainstem (𝛼𝛼/𝛽𝛽)𝑚𝑚 value is associated with uncertainties, it is con-
sidered to be between 2 and 3 Gy (Clark et al., 1998; Mayo et al., 2010; 
Meeks et al., 2000; Orton & Cohen, 1988). For such a low (𝛼𝛼/𝛽𝛽)𝑚𝑚 the RBE 
is assumed to increase. Furthermore, in regard to pediatric patients, these 
children are generally small in size compared to grown adults and are there-
fore typically treated with low range proton beams with smaller modulation 
widths. This results in higher LET values, further leading to an increase in 
the RBE (Marteinsdottir et al., 2019; Paganetti, 2014). All of the listed 
factors emphasize the concern of the RBE in the brainstem when treating 
children with brain tumors. 
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6 Thesis objective 
The overall objective of this study was to investigate and explore the 
effects of LET and variable RBE in the brainstem for pediatric patients 
treated with proton therapy. Specifically, this also involved a regional anal-
ysis of the RBE with regard to the substructures of the brainstem. A pre-
requisite for obtaining LET and RBE for these patients was to implement 
a double scattering proton treatment nozzle in a Monte Carlo code. Objec-
tives of each paper included in this thesis are described below. 
Paper I 
• To investigate how different tumor locations relative to the brain-
stem influence the LET and variable RBE within the brainstem. 
• To investigate how different treatment field setups alters the LET 
and variable RBE within the brainstem. 
Paper II 
• To investigate how isodose volumes are influenced by different var-
iable RBE models within both the brainstem and brainstem sub-
structures.  
Paper III 
• To implement the components of a double scattering treatment 
nozzle into a Monte Carlo code. 
• To develop a system to recalculate and investigate variable RBE-
weighted doses within patients treated with double scattering pro-
ton therapy.  
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Paper IV 
• To investigate if elevated LET, and thus increased RBE, contrib-
utes to symptomatic brainstem toxicity for pediatric brain tumor 
patients treated with proton therapy. 
• To investigate if substructures of the brainstem have different sen-
sitivities to LET and RBE regarding symptomatic brainstem tox-
icity. 
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7 Materials and methods 
7.1 Patient material and calculation software 
All patient data used in this PhD project had been anonymized and orig-
inated from the University of Florida Health Proton Therapy Institute 
(UFHPTI). All treatment plans from UFHPTI were DS proton therapy 
plans generated in the Eclipse TPS (Varian Medical Systems, Palo Alto, 
CA, USA). These DS plans were used in Papers III-IV. In Paper I, patient 
data from UFHPTI were replanned using IMPT in Eclipse at Haukeland 
University Hospital. In Paper II, the patient data from UFHPTI were re-
planned using IMPT in Eclipse at Aarhus University Hospital using the 
same dose constraints and treatment field angles as for the original DS plans. 
All IMPT and DS plans in this PhD project were recalculated using the 
FLUKA Monte Carlo code (Battistoni et al., 2016; Böhlen et al., 2014; 
Ferrari et al., 2005). So-called FLUKA user routines were used in order to 
define complex setups regarding properties such as primary particle distri-
butions, scoring quantities, transport events, and dynamic geometry com-
ponents.  
7.2 Recalculation of IMPT plans 
To import treatment plan data into the FLUKA Monte Carlo code for 
recalculation, the CT images as well as plan information must be translated 
into a format readable for FLUKA. CT data can be directly imported using 
Flair (Vlachoudis, 2009), a graphical user interface for FLUKA, while the 
foundation for treatment plan translation and importation had already been 
7.2 Recalculation of IMPT plans  
 
46   
created in Fjæra (2016). Scripts had been developed to generate DAT files 
containing pencil beam information from DICOM files from the initial treat-
ment plans. The information included spot positions and spot sizes, spot 
energies and spot weights, as well as pencil beam directions. During recal-
culation, for each primary particle the FLUKA source user routine was 
called to randomly sample a pencil beam from the treatment plans.  
In order to accurately recalculate the treatment plans, the in-house 
FLUKA recalculation system was calibrated according to the TPS (Paper 
I). A generic HU to material density calibration curve from the TPS was 
linked to the CT images before treatment planning. Furthermore, the treat-
ment plans were generated based on a virtual treatment machine called 
CAP GENERAL, associated with a specific HU to relative stopping power 
calibration curve. In order to avoid differences in dose distributions due to 
different calibration curves, both calibration curves were implemented into 
FLUKA. The HU to material density could be directly imported. For the 
HU to relative stopping power, a total of 64 artificial phantoms of varying 
HUs were created and a 160 MeV pristine Bragg peak for each HU was 
simulated in the TPS. The same simulations were also conducted in FLUKA, 
the range differences between the TPS and FLUKA were analyzed and stop-
ping power scaling factors reflecting the range differences were employed in 
FLUKA such that equal ranges for each HU were calculated in both systems. 
Material definitions for specific HU intervals were defined according to the 
methods of Schneider et al. (2000) and Parodi et al. (2007). 
Energy spreads were approximated to a value of 0.9% of the initial beam 
energy for the entire energy range in Paper I. In preparation for Paper II, 
  7 Materials and methods 
 
  47 
the energy spreads were tuned and defined as a variable function of the 
initial beam energy. To define the energy spread calibration curve, eight 
pristine Bragg peaks with energies between 70-250 MeV were created in the 
TPS. These were recalculated using an initial energy spread of 0.9% in 
FLUKA. The width differences between the TPS and FLUKA at the 80% 
distal dose for each peak were compared. If the width difference was > 1 
mm, the energy spread in FLUKA was adjusted and the Bragg peak was re-
simulated until differences were below 1 mm.  
By default, FLUKA estimates the dose per primary particle. Since clinical 
dose delivery is based on the total dose, it is desirable to obtain absolute 
doses in FLUKA. In Papers I and II, the dose from FLUKA was normalized 
to the mean TPS dose within the PTV. 
7.2.1 Scoring dose to water 
In order to have an unbiased comparison of the FLUKA dose to the TPS 
dose, the dose to water (𝐷𝐷𝑤𝑤) was obtained in FLUKA. Instead of scoring 
the FLUKA dose directly i.e., dose to material, the fluence of all particles 
𝛷𝛷𝑚𝑚 was scored in a grid equal to the one used during the initial treatment 
planning. Using the fluscw user routine, for each particle interaction, the 







where 𝑖𝑖 specifies the particle type, 𝐿𝐿𝑑𝑑𝐿𝐿𝑚𝑚,𝑤𝑤 is the unrestricted LET in water 
for particle 𝑖𝑖 and 𝜌𝜌𝑤𝑤 is the water density. The 𝐿𝐿𝑑𝑑𝐿𝐿𝑚𝑚,𝑤𝑤 is obtained using the 
7.2 Recalculation of IMPT plans  
 
48   
FLUKA GETLET function where the density of the material can be over-
ridden to water regardless of the actual material. 
7.2.2 Scoring dose-averaged LET 
In preparation for Paper I, a method was implemented in FLUKA to 
obtain the LETd using the fluscw routine in conjunction with an offline 
Python script. By utilizing equations (2.8) and (7.1) the LETd (in water) in 








 , (7.2) 
where 𝑖𝑖 only included primary and secondary protons. The quantities in the 
numerator and denominator were scored separately in FLUKA, while the 
division was performed offline. 
7.2.3 Implementing variable RBE models  
 Our research group performed a literature search to obtain all phenome-
nological LQ based RBE models for protons published per November 2017. 
All models were rephrased to have a common formalism as mentioned in 
section 3.2.5 and further detailed in Rørvik et al. (2018). This was done in 
order to simplify both model comparison and the implementation into the 
FLUKA recalculation system. Since the LQ based linear phenomenological 
models use the LETd to quantify the RBE (Rørvik et al., 2018), the LETd 
from equation (7.2) was used to calculate 𝑅𝑅𝑅𝑅𝑑𝑑𝑚𝑚𝑚𝑚𝑚𝑚  and 𝑅𝑅𝑅𝑅𝑑𝑑𝑚𝑚𝑚𝑚𝑚𝑚  for the 
models. These quantities were calculated offline on a voxel-by-voxel basis. 
Furthermore, the 𝑅𝑅𝑅𝑅𝑑𝑑𝑚𝑚𝑚𝑚𝑚𝑚 and 𝑅𝑅𝑅𝑅𝑑𝑑𝑚𝑚𝑚𝑚𝑚𝑚, a user-defined (𝛼𝛼/𝛽𝛽)𝑚𝑚 as well as 
the dose from equation (7.1) (divided by the number of fractions) were 
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inserted into equation (3.7) to obtain the variable RBE in each voxel for a 
given model. For the non-linear RBE models that rely on the LET spectrum, 
𝑅𝑅𝑅𝑅𝑑𝑑𝑚𝑚𝑚𝑚𝑚𝑚 and 𝑅𝑅𝑅𝑅𝑑𝑑𝑚𝑚𝑚𝑚𝑚𝑚 were calculated online in the fluscw routine using the 
following equations: 












where 𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚 and 𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚 are biological weighting functions for a specific non-
linear RBE model (Rørvik et al., 2017). 
7.2.4 Patient simulations 
In Paper I, CT scans of a five-year-old male diagnosed with ependymoma 
were used as a foundation for the treatment plans. To investigate how tumor 
location and treatment field angles influence the LET within the brainstem, 
the target volume was shifted into four different positions relative to the 
brainstem. A variety of different treatment field angles was also defined as 
well as different IMPT spot spacings. This resulted in 11 different treatment 
plans and a total of 33 treatment field each separately simulated using 30 
million primary particles. 
In Paper II, three pediatric patients with brain tumors were recalculated 
in FLUKA using 50 million primaries per treatment field. The spatial over-
lap of isodose curves from variable RBE models using different (𝛼𝛼/𝛽𝛽)𝑚𝑚 val-
ues were evaluated and compared with isodose curves from RBE1.1 doses 
using so-called Dice similarity coefficients (Dice, 1945). 
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7.3 Recalculation of DS plans 
The majority of methods outlined in the previous section for IMPT in-
cluding the calculation of 𝐷𝐷𝑤𝑤, LETd and variable RBE were also used when 
recalculating DS plans. 
7.3.1 Implementing and calibrating a treatment nozzle 
In order to recalculate the DS plans for patients treated at the UFHPTI, 
the treatment nozzle had to be implemented into FLUKA (Paper III). The 
nozzle was a so-called universal nozzle and was installed by IBA (Ion Beam 
Applications, Belgium). The IBA universal nozzle consists of the following 
main components that the proton beam interacts with (from upstream to 
downstream): first ionization chamber, first scatterers, RM wheels, second 
scatterers, variable collimators, second ionization chamber, field mirror and 
snouts as well as patient specific apertures and range compensators. Based 
on blueprints provided by IBA through UFHPTI, the geometry of these 
components was created in FLUKA (Figure 7.1). While most components 
could be defined using simple geometry definitions, RM wheels and patient 
specific components required more advanced solutions.  
Each RM wheel in the IBA nozzle is associated with 255 BCM weights 
that fine-tune the SOBP flatness by specifying the beam intensities. Each 
BCM weight covers an angle span of 365°/255 ≈ 1.43°. To model a rotating 
RM wheel, the source routine in FLUKA was used to define a weighted 
random sampling algorithm that emulates a time-dependent rotation. For 
each primary particle, a BCM weight alongside the specific weight position 
on the wheel is sampled and the wheel is rotated accordingly. Given 
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sufficient statistics, this method generates indistinguishable results com-
pared to a continuously time-dependent rotating wheel. 
 
 
Figure 7.1 The nozzle at UFHPTI implemented in FLUKA. Component distances have 
been reduced for better visibility. Some components are interchangeable; thus, all compo-
nent varieties are not shown such as other RM wheels, second scatterers or snouts. Mod-
ified from the Flair geometry viewer module. 
To generate patient specific apertures and compensators, a Python script 
was built that automatically creates the components in FLUKA. As FLUKA 
relies mainly on text-based input, the components were defined using simple 
ASCII files.  
In contrast to the IMPT recalculation system which had been calibrated 
to the TPS, the DS recalculation system was calibrated towards measure-
ments in water phantoms conducted during the commissioning of the treat-
ment facility back in 2006. Measurement data of ranges from pristine Bragg 
peaks of various energies were collected. The measurement setups for each 
Bragg peak were defined in FLUKA and the Bragg peaks were simulated. 
Range differences between measurements and FLUKA simulations were 
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registered, and the initial beam energy defined in FLUKA was adjusted 
accordingly to minimize the range differences. Energy spreads were also cal-
ibrated using a similar method as for the IMPT system, however, with a 
decrease in the permitted differences between FLUKA and measurements. 
Furthermore, the geometry implementation of the treatment nozzle in 
FLUKA was verified by comparing SOBPs and lateral profiles from FLUKA 
and measurements using a variety of ranges and modulation widths, aper-
ture openings, and range compensators. 
As the final objective of the DS implementation was to recalculate pa-
tients treated at UFHPTI, calibration curves to obtain absolute doses in 
FLUKA were defined. Furthermore, dose comparisons between FLUKA and 
the TPS for a set of patients were conducted. While calibration curves for 
absolute dose can be defined as a simple function of initial beam energy for 
IMPT (Jakel et al., 2004), in DS the relationship between the dose and the 
number of primary particles is highly dependent on the range and modula-
tion width for a given SOBP. Thus, multiple calibration curves for small 
SOBP range spans were defined, where each curve provided the relationship 
between the modulation width and the number of particles per unit dose. 
To reduce the lateral spread in air, patients are typically treated with an 
air gap as small as feasible, and distances of 2 cm between the patient and 
the compensator are not unusual. This can lead to an overlap between the 
compensator and the so-called voxel cage surrounding the patient, which 
was the case for most patients in Paper IV. This was partly solved by crop-
ping the voxel cage as tightly as possible. However, cropping was sometimes 
not sufficient, and a two-step simulation method was developed by utilizing 
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a phase space file. In step one of the phase space simulation, all primary 
particles are simulated and when a certain particle reaches the downstream 
part of the compensator, the particle type, position, kinetic energy, as well 
as direction are recorded into a phase space file using the FLUKA mgdraw 
user routine. In step two, the entire treatment nozzle, including the aperture 
and compensator, are removed from the simulation environment, and only 
the patient is included. The source routine is used to read each line from 
the phase space file and particles from the file are subsequently simulated. 
These particles start within the voxel cage, resolving the issue of overlapping 
components. 
7.3.2 Patient simulations 
A total of 36 pediatric brain tumor patients were selected for the case-
control study in Paper IV. Each case with symptomatic brainstem injury 
was matched with three controls based on age (± 1.5 years), diagnosis, ad-
juvant therapy, and brainstem dose parameters (D10% ± 2 Gy(RBE), and 
maximum dose; D0.1cc ± 2 Gy(RBE)). Since many particles stops within the 
DS nozzle and never reach the patient, each treatment field was simulated 
using 600 million primary particles to obtain statistical uncertainties below 
1% in the target volume. Differences in LETd, RBE, and variable RBE-
weighted doses from RBE models were compared in brainstem and brain-
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7.4 Ethical considerations 
The patient data used in all papers originated from UFHPTI. All patient 
data were anonymized, and the usage of the patient data was approved by 
an UFHPTI institutional review board. 
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8 Summary of results 
8.1 Paper I: LET variation depending on tumor location 
The evaluated tumor locations relative to the brainstem were full overlap 
(FO), half overlap (HO), juxtaposed posterior (JP) and 1 cm posterior 
(1cmP) (Figure 8.1). One posterior and two lateral treatment fields were 
used.  
A high LETd edge was seen at the distal part of the treatment fields 
surrounding the tumor volume. For tumor locations JP and 1cmP, the LETd 
in the brainstem was most pronounced with mean values of 5.9 keV/μm 
and 6.6 keV/μm, respectively, compared to a mean LETd in the brainstem 
3.2 keV/μm and 4.5 keV/μm for FO and HO, respectively.  
To obtain variations in the biological effect due to LET, the physical dose 
was multiplied with the LETd and a factor c (i.e., 𝑅𝑅𝑅𝑅𝑑𝑑𝐿𝐿𝐿𝐿𝐿𝐿 = 1 + 𝑐𝑐 · 𝐿𝐿𝑑𝑑𝐿𝐿𝑑𝑑), 
termed the LET weighted dose (LWD). The value of c was set to provide a 
mean RBE of 1.1 within a certain region in the target volume. The highest 
mean and maximum LWD in the brainstem were seen for the FO case 
(maximum LWD = 63 Gy(RBE)), with decreasing LWD for increasing dis-
tance between tumor and brainstem due to the decrease in physical dose 
(maximum LWD for 1cmP = 35.5 Gy(RBE) (Figure 8.1). 
By changing the treatment field angles for the JP plan, the mean LETd 
was reduced to 4.0 keV/μm by using a vertex posterior treatment field in 
combination with two lateral anterior fields. However, the selected field an-
gles also increased the physical dose slightly compared to the original plan. 
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The spot spacing was adjusted between 3 to 9 mm. While the mean brain-
stem LETd remained unchanged, the 9 mm spot spacing introduced an in-
crease in the LWD of 6%. 
 
Figure 8.1 Axial view of physical doses, LETd, RBELET and dose difference between using 
RBE1.1 and RBELET for the various tumor locations. Voxels receiving doses below 0.01% 
of the prescription dose are set transparent. The figure is reprinted from Paper I with 
permission from Taylor & Francis Group. 
8.2 Paper II: Spatial agreement of variable RBE models 
The spatial agreement between isodose volumes from RBE1.1 and from the 
phenomenological RBE models of Rørvik et al. (2017) (ROR), McNamara 
et al. (2015) (MCN), Wedenberg et al. (2013) (WED), Carabe et al. (2012) 
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(CAR) as well as the plan-based LET-weighted dose (LWD) (Unkelbach et 
al., 2016) were investigated. The spatial agreement was compared for each 
5 Gy(RBE) dose level and quantified using Dice similarity coefficients 
(DSCs) where DSC = 1 represents full overlap while DSC = 0 represents 
no overlap. DSCs, doses and RBE were studied for the full brainstem, mid-
brain, pons, and medulla oblongata in three patients diagnosed with crani-
opharyngioma, low-grade glioma, and ependymoma.  
In general, the spatial agreement between RBE1.1 and all the variable RBE 
models decreased for increasing isodose levels. Furthermore, isodoses from 
phenomenological models consistently enclosed the RBE1.1 isodoses. The 
LWD also fully enclosed the RBE1.1 except for a few isodose levels and 
structures, where a negligible shift between the isodose curves occurred.  
The patient with ependymoma had the largest variation in dosimetric 
volumes and DSCs across the models. The V50Gy(RBE) in the brainstem in-
creased from 32% using RBE1.1 up to 49% for WED. Simultaneously, the 
spatial agreement showed in this case a DSC of 0.79 for WED, and 0.95 for 
LWD (Figure 8.2). 
The applied (𝛼𝛼/𝛽𝛽)𝑚𝑚 values were also varied between 2.1, 2.5 and 3.3 Gy 
for the phenomenological models, where a considerable decrease in the var-
iable RBE-weighted dose was seen for increasing (𝛼𝛼/𝛽𝛽)𝑚𝑚.  
Considering that high dose levels introduce decreasing spatial agreement, 
the effect of a variable RBE is most pronounced for higher dose and small 
volumes, where constraints commonly are applied in clinical settings. 
8.3 Paper III: Implementation of a DS nozzle in a MC system  
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Figure 8.2 V50Gy(RBE) metrics and corresponding Dice similarity coefficients within the full 
brainstem and brainstem substructures for the three patients. An (𝛼𝛼/𝛽𝛽)𝑚𝑚 of 2.1 Gy was 
used for the phenomenological models. The figure is reprinted from Paper II under the 
CC BY-NC-ND 4.0 license. 
8.3 Paper III: Implementation of a DS nozzle in a MC system 
The main components of the DS nozzle at UFHPTI were implemented 
into the FLUKA Monte Carlo code in Paper III. In order to accurately 
recalculate treatment plans, the implementation was calibrated and verified 
by comparisons with measurements conducted in water phantoms. 
In general, good agreement between FLUKA and measurements was 
achieved. Range differences between FLUKA and measurements for pristine 
Bragg peaks were used for range calibration, and SOBPs were used for range 
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verification. After calibration, range differences were within ±1 mm for 26 
out of 28 investigated SOBPs. Observed differences in modulation widths 
between FLUKA and measurements were within ±2 mm for 22 of the 28 
SOBPs, while the remaining were within ±5 mm (Figure 8.3a).  
Verification of the aperture collimation showed an agreement within ±1 
mm for 80%-20% lateral penumbras for all aperture openings at several 
depths (Figure 8.3b). Using a range compensator in FLUKA resulted in 
range differences within 1 mm when compared to measurements. 
Lastly, treatment plans for two previously treated patients were recalcu-
lated in FLUKA as a verification procedure, also obtaining LETd and vari-
able RBE for the patients. The mean PTV dose difference between the TPS 
and FLUKA for the two patients were between 0.4%-1.4%. Gamma pass 
rates (3%/3mm) were between 90%-99% in the full brain. 
 
Figure 8.3 (a) Spread-out Bragg peaks for five combinations of ranges and modulation 
widths. (b) Lateral profiles for 3×3 cm2, 6×6 cm2 and 10×10 cm2 aperture openings. The 
figure is adapted from Paper III under the CC BY-NC-ND 4.0 license. 
8.4 Paper IV: Variable RBE and pediatric brainstem toxicity 
The RBE1.1 dose, LETd as well as variable RBE and RBE-weighted doses 
were investigated in a 1:3 case-control study. The cohort included 36 
8.4 Paper IV: Variable RBE and pediatric brainstem toxicity  
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pediatric brain tumor patients where nine had experienced symptomatic 
brainstem toxicity. The brainstem substructures: midbrain, pons, and me-
dulla oblongata were delineated. To approximate physiologic fiber tracts, 
further substructures of the pons were delineated using four transversal 
zones: pons posterior, pons middle posterior, pons middle anterior, and pons 
anterior. The variable RBE models included the phenomenological model of 
Rørvik et al. (2017) (ROR) and the LET-weighted dose (LWD) (Unkelbach 
et al., 2016). 
Median and maximum LETd were on average greater for cases compared 
to controls for all substructures as well as the full brainstem (Figure 8.4). 
Differences between cases and controls generally increased for the maximum 
LETd compared to the median. The largest relative of difference of 18% in 
maximum LETd between cases and controls occurred for the midbrain and 
brainstem core. 
The median RBE1.1 dose for cases was on average slightly higher compared 
to controls for the majority of substructures. When these substructures were 
evaluated using the ROR model and LWD the differences between cases 
and controls increased. For instance, the average difference in dose to the 
midbrain was 0.7 Gy(RBE) for RBE1.1, increasing to 1.5 Gy(RBE) for both 
ROR and LWD. In contrast, for the remaining structures where the RBE1.1 
dose was lower for cases compared to controls, these differences decreased 
when evaluating the RBE-weighted dose using ROR and LWD. These 
trends were also widely apparent for when comparing cases and controls in 
each group separately. 
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Overall, there was a large variation in both LET and RBE within cases 
and controls, with generally higher LET and RBE in the brainstem for cases. 
Patients at high risk of brainstem toxicity might therefore benefit from in-
dividual assessment of LET/RBE.  
 
Figure 8.4 Median LETd (a) and maximum LETd (b) for cases (red) and controls 
(gray/black) in relevant structures. Horizontal lines show average values for cases and 
controls, while the vertical error bars depict 95% confidence intervals. Only the LETd in 
voxels receiving doses over 1 Gy(RBE1.1) has been considered. Abbreviations: Core = 
Brainstem core, Surf. = Brainstem surface, Med. obl. = Medulla oblongata, Post. = Pons 
posterior, Mid. post. = Pons middle posterior, Mid. ant. = Pons middle anterior, and Ant. 
= Pons anterior.
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9 Discussion 
It is well known, from both in vitro and in vivo experiments, that the 
RBE for protons varies with the dose level, tissue type, LET, and biological 
endpoint. Despite this knowledge, clinical proton therapy practice has been 
operating with a fixed RBE of 1.1. Considering that the ill-effects of proton 
therapy have been generally low and clinical evidence of a varying RBE has 
been absent, the RBE of 1.1 has by many considered an acceptable approx-
imation. However, since 2016, clinical evidence of a variable RBE has begun 
to emerge - with multiple studies indicating a correlation between radiation 
toxicity and RBE (Bahn et al., 2020; Bolsi et al., 2020; Eulitz et al., 2019b; 
Peeler et al., 2016; Underwood et al., 2018; Wang et al., 2020; Ödén et al., 
2020).  
While clinical practice has been based on a fixed RBE, treatment planners 
have been aware of the potential dangers of elevated LET and RBE at the 
end of treatment fields. As a measure to circumvent this threat (as well as 
proton range uncertainties), beam angles are carefully selected to prevent 
beams pointing directly towards OARs (Haas-Kogan et al., 2018; Indelicato 
et al., 2014; Paganetti et al., 2019). However, these measures have been 
adapted based on passive scattering proton therapy. With the ongoing ad-
vancement towards PBS, protons will not only be delivered more precisely, 
but an increase in both LET values as well as LET hot spots is expected 
(Grassberger et al., 2011). While adjustment of beam angles is feasible also 
in PBS (Paper I), without a visual representation of the LET, such measures 
might prove difficult to conduct without proper visual representation of the 
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LET. The change towards PBS, coupled with the emerging studies showing 
the correlation between variable RBE and toxicity, warrants the implemen-
tation of LET and variable RBE calculation in proton therapy clinics. 
9.1 Does the variable proton RBE have a clinical impact on pa-
tients? 
As mentioned above, multiple clinical studies have in recent years shown 
a correlation between toxicity and increased RBE. The majority has studied 
asymptomatic toxicity (Bahn et al., 2020; Bolsi et al., 2020; Eulitz et al., 
2019b; Peeler et al., 2016; Underwood et al., 2018; Ödén et al., 2020), char-
acterized as grade 1 based on the Common Terminology Criteria for Adverse 
Events (CTCAE, 2020), assessed from image changes on either CT or MR 
images. One study has also identified a correlation between increased RBE 
and symptomatic rib fracture after proton therapy of breast cancer (Wang 
et al., 2020). Nevertheless, other studies have also investigated the effect of 
variable RBE on toxicity without finding any clear correlation (Giantsoudi 
et al., 2016; Niemierko et al., 2021). 
There are many factors that complicates the task of acquiring enough 
patients to detect a significant correlation between RBE and toxicity. In 
the case of symptomatic toxicity following proton therapy, reported num-
bers are generally low. Furthermore, for instance in the case of symptomatic 
brainstem toxicity, symptoms have been reported over two years after the 
start of treatment (Giantsoudi et al., 2016) which is longer than the follow-
up for some patients (Haas-Kogan et al., 2018). Studying asymptomatic 
toxicity has a contrasting issue as short intervals between surgery and 
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radiation treatment are associated with a higher risk of image changes 
(Gunther et al., 2015). Moreover, a challenge for studies of both sympto-
matic and asymptomatic toxicity is to distinguish between radiation in-
duced injury and tumor progression or recurrence (Luhr et al., 2018a; Mayo 
et al., 2010). This might have contributed to the relatively low number of 
patients included in some of the studies. The total number of patients in-
cluded ranged between 3 (Ödén et al., 2020) to 203 (Wang et al., 2020), and 
the number of patients with reported toxicity ranged from 3 (Ödén et al., 
2020) to 23 (Bahn et al., 2020). 
A portion of the studies also designed regression models (Bahn et al., 2020; 
Eulitz et al., 2019b; Peeler et al., 2016) to predict the probability of image 
change on a voxel-by-voxel basis. While including many voxels with and 
without necrosis provides lots of data points, it does not increase the number 
of patients. Moreover, as pointed out by Niemierko et al. (2021), voxel-
based regression models require independence between voxels which is not 
the case for patients treated with radiotherapy.  
In general, a fundamental issue regarding the correlation between 
LET/RBE and asymptomatic toxicity is that it is difficult to predict if im-
age changes will lead to symptoms (Gunther et al., 2015). This, coupled 
with the generally low number of patients in the studies, complicates the 
task of providing indisputable evidence of the clinical impact of the variable 
RBE. Hence, larger studies and more data on patients, preferably with 
symptomatic toxicity, are required. 
 
 
9.2 The need for variable RBE models  
 
66   
9.2 The need for variable RBE models 
Phenomenological RBE models are based on in vitro experiments using 
clonogenic cell survival as an endpoint (Rørvik et al., 2018). It is, however, 
well-known that the RBE varies across different endpoints, and with that 
comes many associated uncertainties. An ongoing discussion is how relatable 
the RBE for cell survival is to damage to normal tissue (Haas-Kogan et al., 
2018). It is uncertain to what degree the RBE for cell survival can be asso-
ciated with late effects such as lung fibrosis or spinal cord injury. Neverthe-
less, studies have indicated a correlation between RBE and lung fibrosis for 
proton therapy patients (Underwood et al., 2018) and in vivo experiments 
on rat spinal cords have shown higher RBE for increasing LET (Saager et 
al., 2018). Furthermore, considering that the experiments for cell survival 
typically have been conducted at doses above 2 Gy, it is expected that RBE 
for normal tissues and OARs could be higher since these are typically lo-
cated in regions of low dose, as well as high LET. Normal tissues are also 
often associated with low (𝛼𝛼/𝛽𝛽)𝑚𝑚 values further increasing the RBE (Pa-
ganetti et al., 2019). 
The RBE calculated from phenomenological RBE models is influenced by 
the selected 𝛼𝛼𝑚𝑚 and 𝛽𝛽𝑚𝑚 or simply the (𝛼𝛼/𝛽𝛽)𝑚𝑚 ratio. These parameters are 
associated with large uncertainties (van Leeuwen et al., 2018). For instance, 
the brainstem (𝛼𝛼/𝛽𝛽)𝑚𝑚 ratio has been estimated to be 2.1, 2.5 and 3.3 Gy 
(Mayo et al., 2010). While these values are not that far apart, the difference 
in the median RBE in the brainstem between using (𝛼𝛼/𝛽𝛽)𝑚𝑚 = 2.1 and 3.3 
could be as much as 20% for variable RBE models, as demonstrated in 
Paper II. Furthermore, as different tissues and tumors are associated with 
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different (𝛼𝛼/𝛽𝛽)𝑚𝑚 ratios, it might become challenging to select which (𝛼𝛼/𝛽𝛽)𝑚𝑚 
ratio to use for RBE modelling when such tissues are overlapping.  
Bearing in mind the abovementioned uncertainties of variable RBE mod-
els, the current practice of RBE of 1.1 does not avoid the issues regarding 
(𝛼𝛼/𝛽𝛽)𝑚𝑚 uncertainties, dose, endpoint or LET dependencies, it merely disre-
gards them. While both the RBE of 1.1 as well as phenomenological models 
are based on biological data (the former deducted as an average value), the 
variable RBE models at least quantifies an increase in RBE for elevated 
LET - a relationship that is difficult to dispute. Although the data sets used 
by RBE models have large uncertainties, focus on reducing these uncertain-
ties for future experiments should be emphasized to improve the RBE mod-
els. 
For instance, many studies on in vitro experiments have not reported LET 
values, and some have also neglected to report 𝛼𝛼 and 𝛽𝛽 values. This has 
resulted in the necessity of simulating the LET as well as fitting the curves 
to obtain the 𝛼𝛼 and 𝛽𝛽 values (Paganetti, 2014). Consistent experimental 
setup and proper reporting of dose, LET and 𝛼𝛼  and 𝛽𝛽  are therefore 
measures that can be taken to reduce uncertainties in the data sets 
(Paganetti et al., 2019). 
Furthermore, in order to create RBE models better suited for normal tis-
sue damage prediction, more relevant data sets in the form of in vivo exper-
iments could be used. Indeed, recent in vivo experiments have also indicated 
a correlation between LET and RBE (Sørensen et al., 2017; Saager et al., 
2018). However, it should be mentioned that in vivo experiments are not 
only much more costly, but also more difficult to conduct consistently 
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(Paganetti et al., 2019; Sørensen, 2019). Sufficiently accurate in vivo RBE 
values might therefore prove challenging to obtain (Haas-Kogan et al., 2018).  
As shown in Paper II, also supported by other studies (Bertolet & Carabe-
Fernandez, 2020; Giovannini et al., 2016; Pedersen et al., 2017; Yepes et al., 
2019; Ödén et al., 2017), published RBE models estimate considerable dif-
ferent RBE values, and does not necessarily follow the same dependencies, 
in particular for (𝛼𝛼/𝛽𝛽)𝑚𝑚 (McMahon, 2021; Rørvik et al., 2018). If current in 
vitro based RBE models were to be implemented in a clinical setting, dif-
ferences among the RBE models could be an obstacle. However, the selection 
of data points by many of the models are often limited, and both data points 
and model assumptions can be irrelevant for a clinical setting. By applying 
specific criteria for data points and dependencies that best reflect a clinical 
scenario, the number of appropriate RBE models can be substantially re-
duced (Otterlei et al., 2021). Furthermore, many of the clinically relevant 
models strongly correlate on the LET dependency, however, with significant 
disagreement regarding (𝛼𝛼/𝛽𝛽)𝑚𝑚 values (McMahon, 2021).  
A common argument against using phenomenological RBE models in clin-
ical research is the lack of clinical validation. This is unfortunate, as by not 
including current RBE models for clinical data studies, validation will never 
be attained (McMahon, 2021). For instance, many studies investigating the 
correlation between RBE and toxicity have excluded the usage of phenom-
enological RBE models and rather used LET or LET-weighted dose, exclu-
sively. While this approach avoids the potential uncertainties that are asso-
ciated with many RBE models, and in particular (𝛼𝛼/𝛽𝛽)𝑚𝑚 uncertainties, op-
portunities in coupling current models with toxicity in a clinical aspect are 
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also missed. By including multiple RBE models on large patient groups in 
toxicity studies, certain models may stand out as better predictors for var-
ious endpoints. 
9.3 Implementing LET and RBE calculation in clinics 
To obtain LET and variable RBE for clinical treatment scenarios, soft-
ware capable of obtaining such quantities must be available at proton facil-
ities. In this PhD project, the FLUKA Monte Carlo code (Battistoni et al., 
2016; Böhlen et al., 2014; Ferrari et al., 2005) was used to estimate dose, 
LET and RBE. Other alternative MC codes include MCNPX (Los Alamos 
National Laboratory, 2002), Geant4 (Agostinelli et al., 2003) and TOPAS 
(Perl et al., 2012). A prerequisite of using MC codes for these purposes is 
that treatment facility specific information such as beam line geometry and 
beam information must be implemented and commissioned, in particular for 
passive scattering proton therapy as was done in Paper III. This is generally 
regarded as a time consuming and resource intensive process. Nevertheless, 
as the benefits are significant, it has still been done at several proton treat-
ment facilities (Engelsman et al., 2009; Grevillot et al., 2011; Herault et al., 
2005; Lutz et al., 2021; Newhauser et al., 2005; Paganetti et al., 2004; Parodi 
et al., 2012; Prusator et al., 2017; Sayah et al., 2013; Shin et al., 2017). In 
addition, the implemented IMPT recalculation system (Paper I) has also 
been used in multiple studies from our research group (Dahle et al., 2020; 
Otterlei et al., 2021; Rørvik et al., 2018; Ytre-Hauge et al., 2020), investi-
gating aspects not feasible in standard treatment planning systems.  
9.4 Scoring of quantities  
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Perhaps the biggest disadvantage of using Monte Carlo simulations in a 
clinical setting is the required calculation time necessary for a sufficiently 
low statistical uncertainty. In particular for passive scattering proton ther-
apy, the majority of the primary particles are stopped in the treatment 
nozzle. It is, however, possible to reduce calculation times by employing 
different variance reduction techniques such as particle splitting and Rus-
sian roulette (Eulitz et al., 2019a; Mendez et al., 2015; Ramos-Mendez et 
al., 2013). Furthermore, GPU-based MC algorithms are also beginning to 
gain popularity, offering a tremendous decrease in calculation time, compa-
rable to analytical algorithms (Beltran et al., 2016; Giantsoudi et al., 2015; 
X Jia et al., 2012).  
There have also been published both analytical (Bertolet et al., 2020; Choi 
et al., 2018; Sanchez-Parcerisa et al., 2016; Wilkens & Oelfke, 2003) as well 
as simplified MC based algorithms (Yepes et al., 2019) for calculating LET 
and RBE. Furthermore, while standard available treatment planning sys-
tems does not support calculating LET or variable RBE (Luhr et al., 2018b; 
Mohan & Grosshans, 2017), there is ongoing development regarding imple-
menting such capabilities in TPSs (Bertolet et al., 2020; Ödén et al., 2017). 
Nevertheless, it is important to keep in mind that by not using full Monte 
Carlo, calculation time will be reduced at the cost of precision. 
9.4 Scoring of quantities 
In proton therapy, the LETd is the most commonly applied method of 
averaging the LET and most phenomenological RBE models depends on the 
LETd (Rørvik et al., 2018). The LETd is often considered the most appro-
priate averaging method for RBE modelling since dose is also closely related 
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to the biological effect of particles (Grun et al., 2019). For these reasons, 
the LETd as well as LET spectra (for non-linear RBE models) were used 
exclusively in this PhD project. The alternative, LETt, is considered to be 
more relevant at higher LET radiation such as carbon ions which have a 
reduced number of particle tracks compared to protons (Grassberger & 
Paganetti, 2011). 
Furthermore, the LET was scored only considering primary and secondary 
protons. A recent review by Kalholm et al. (2021) found that the majority 
of published studies involving quantification of the RBE for protons used 
LET counting only primary and secondary protons. There is, however, no 
obvious consensus on which particles to include. Grassberger and Paganetti 
(2011) have demonstrated the importance of including secondary protons 
for LET calculations. Another study has showed that by neglecting to con-
sider heavier ions, the LET could be up to 50% lower compared to when 
including all particles (Grzanka et al., 2018). While there is not necessarily 
a specific LET that is more correct than others, the most important factor 
is to be consistent and to accurately report the averaging method and in-
cluded particles for the LET calculation (Kalholm et al., 2021). 
Dose to water has traditionally been reported in radiotherapy (Liu et al., 
2002). Scoring quantities in water in Monte Carlo codes has certain ad-
vantages. As clinical experience and dosimetric protocols in radiotherapy 
are water based, scoring the same quantity in MC codes makes it easier to 
relate the results to clinical experience. Although dose to water in proton 
therapy has been reported up to 10% higher compared to dose to medium 
in areas of high density, differences were generally within 1% for normal 
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density tissue (Paganetti, 2009). For comparison purposes, the dose to water 
was scored throughout this PhD project. Naturally, the LET to water in-
stead of LET to medium was therefore also scored, although significant dif-
ferences between water-based and medium-based LET for bony material 
have been reported as well (Wilkens & Oelfke, 2004b). Hence, by neglecting 
the elemental composition of the medium, the improved accuracy of MC 
codes might be slightly reduced. 
For all patient recalculations, quantities were scored volumetrically using 
the same grid and resolution as used during the initial treatment planning. 
Scoring grid voxels from TPSs are typically larger compared to CT voxels. 
Larger voxels have the advantage of increasing tracking efficiency for Monte 
Carlo. Furthermore, by using the same grid for the MC calculations and the 
TPS, voxel-by-voxel comparisons are simpler to achieve. However, it is im-
portant to keep in mind that by scoring on a grid that is not equal to the 
CT grid, scoring voxels may contain CT voxels of different material compo-
sitions. This requires that the MC code defines an average material compo-
sition within the scoring voxel, a process that is not always well defined 
(Paganetti et al., 2008). 
9.5 Should current clinical practice be revised? 
Using a constant RBE simplifies dose calculation and keeps consistency 
between treatment facilities. Moreover, if the RBE of 1.1 was to be discarded, 
it is not clear what new fixed RBE or which variable RBE model to use. As 
previously mentioned, variable RBE models still lacks clinical validation. 
Using the incorrect RBE model may not only lead to overdosage of healthy 
tissue, but also underdosage of the tumor.  
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While there are indications of a variable RBE both in vitro, in vivo and 
from clinical investigation, over 150 000 patients have been treated based 
on an RBE of 1.1 with no unreasonable numbers of reported toxicities (Luhr 
et al., 2018b). Nevertheless, the relatively low incidence of toxicity from 
historical data may be partly attributed to the clinical practice of avoiding 
beams stopping directly in front of critical organs. Furthermore, when 
higher than expected toxicity has emerged, a practice has been to reduce 
prescription doses (Mohan et al., 2017b). While such measures might lead 
to decreased normal tissue damage, it may also compromise tumor control, 
limiting the true potential of proton therapy, and potentially masking the 
consequences of an increased RBE. 
Furthermore, the proton therapy community is currently undergoing a 
progression from passive scattering proton therapy to PBS, and more spe-
cifically IMPT. As mentioned, while IMPT increases the dose conformity it 
also leads to higher LET values (Grassberger et al., 2011). This might com-
promise the dosimetric advantage of IMPT when considering the variable 
RBE-weighted dose (Giantsoudi et al., 2018). Moreover, while the effects of 
LET and variable RBE from current published studies are not entirely con-
cise, new advancements in proton therapy such as image guidance will fur-
ther increase the dose precision and reduce the potentially smeared-out LET 
values. Such advancements might increase the effects of the variable RBE 
(Luhr et al., 2018a).  
IMPT also provides the ability to increase the difference in biological ef-
fect for normal tissue and tumors by so-called LET optimization. By opti-
mizing each individual beam spot, high LET can be moved and maximized 
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inside the target region and/or minimized inside critical organs, while still 
maintaining the physical dose distribution within the target (Cao et al., 
2017; Giantsoudi et al., 2013; Grassberger & Paganetti, 2017; Inaniwa et al., 
2017; Unkelbach et al., 2016). The MD Anderson Cancer Center has initi-
ated an ongoing phase 1 clinical trial investigating the use of LET optimi-
zation for pediatric patients with ependymoma (MD Anderson Cancer 
Center, 2018).  
While proton therapy clinics might not yet be ready to disregard the RBE 
of 1.1, clinics should start the implementation of LET and variable RBE 
calculation for plan evaluation and as a visualization tool. With the increas-
ing number of patients treated with proton therapy, more data on LET and 
RBE can then be collected over time that can be used to revise and improve 
current RBE models, and in particular provide valuable data for studies on 
the clinical impact of a variable RBE. Furthermore, patients at high risk of 
fatal toxicity would clearly benefit from individual assessment of LET and 
variable RBE, which is demonstrated in Paper IV. 
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10 Conclusions 
Consideration of the LET and variable RBE is particularly important for 
children with brain tumors. These tumors are often located in close proxim-
ity of the brainstem, a critical organ for vital life functions. Great variation 
in the LET in the brainstem was seen dependent on the relative location of 
the tumor and brainstem. While altering field angles reduced the LET, it 
could also slightly increase the physical dose, indicating that accounting for 
LET and variable RBE-weighted dose clinically may prove difficult without 
tools allowing for quantitative and visual representation. 
Comparing multiple RBE models with RBE1.1 for pediatric brain tumor 
patients revealed that isodose volumes using variable RBE models generally 
surrounded RBE1.1 isodose volumes. The degree of spatial agreement was 
dependent on the RBE model, the applied model specific parameters, and 
with a substantial decrease in agreement for increasing isodose levels. Con-
sidering that current RBE1.1 dose constraints are often defined for high doses 
and small volumes, developing RBE model specific dose constraints are 
therefore crucial for dose optimization based on variable RBE models.  
To enable extraction of LET and variable RBE data from previously 
treated patients, a double scattering nozzle was implemented and commis-
sioned in a Monte Carlo code. The implementation was validated to meas-
urement data and provides a powerful tool for studies on long-term follow-
up data, including LET and variable RBE.  
The nozzle implementation was used in a retrospective case-control study 
of LET and variable RBE and brainstem toxicity. There were large 
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interpatient variations in LET/RBE, but general trends pointed to higher 
LET and RBE for cases compared to controls. The results warrant individ-
ual LET/RBE assessment for high-risk patients.  
The results from this thesis demonstrate the need for clinical implemen-
tation of LET and variable RBE calculation to use for plan evaluation. 
Clinical access to LET/RBE calculation tools would simplify and increase 
the quality of assessing and reducing LET and RBE in critical organs, which 
patients at high risk of toxicity could benefit from. More clinical data on 
LET and RBE will also be of great value to improve future proton therapy 
treatment.  
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